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ABSTRACT OF THE DISSERTATION 
 
New Paradigm of Defibrillation: 
Towards Painless Therapy 
by 
Wenwen Li  
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2011 
Professor Igor R. Efimov, Chairperson 
 
Sudden cardiac death (SCD) causes approximately 300,000 - 400,000 deaths a 
year in the United States. It usually starts as ventricular tachycardia (VT) and 
then degenerates into ventricular fibrillation (VF). Implantable cardioverter 
defibrillator (ICD) therapy is the only reliable treatment of VT/VF and has been 
shown to effectively reduce mortality by many clinical trials. However, high-
voltage ICD shocks could result in myocardial dysfunction and damage. The 
majority of patients receiving ICD therapy have a history of coronary disease; 
their hearts develop myocardium infarction, which could provide a substrate for 
reentrant tachy-arrhythmias. Other than lethal ventricular tachycardia, atrial 
fibrillation (AF) became the most common arrhythmia by affecting 2.2 to 5.6 
 3 
millions of Americans. The complications of AF include an increased rate of 
mortality, heart failure, stroke, etc. 
 
In this dissertation, we explore mechanisms of sustained ventricular and atrial 
tachyarrhythmias and the mechanisms of defibrillation using the conventional 
high-voltage single shock. Through the use of novel fluorescent optical mapping 
techniques and several animal models of ventricular and atrial arrhythmias, we 
develop and validate several novel low-voltage defibrillation therapies for atrial 
and ventricular arrhythmias. Several important previous studies on mechanisms 
of arrhythmia maintenance and termination using mathematical and 
experimental models are overviewed in Chapter 2. A study on multiple 
monophasic shocks improving electrotherapy of ventricular tachycardia in rabbit 
model of chronic infarction is presented in Chapter 3. Ventricular arrhythmias 
and low-voltage defibrillation therapy are studied in a more clinically-relevent in 
vivo canine model of healing myocardial infarction in Chapter 4. Finally, Chapter 
5 presents a novel multi-stage low-energy defibrillation therapy for atrial 
fibrillation in in vivo canine hearts. 
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1 Introduction  
   
1.1 Ventricular Arrhythmia 
  
Sudden cardiac death (SCD) caused by ventricular tachyarrhythmias (VT and VF) 
is the most prevalent immediate cause of mortality, which counts for 300,000-
400,000 deaths per year in the United States 1. SCD most often occurs in patients 
with heart disease. In 90 percent of adult victims of SCD, two or more major 
coronary arteries are narrowed by fatty buildups. Scarring from a prior heart 
attack is found in two-thirds of victims. Patients diagnosed with congestive heart 
failure are also at a high risk for SCD.  
 
Three mechanisms underlie the initiation and maintenance of VT: automaticity, 
triggered activity, and reentry. Abnormal automaticity causes a region of 
ventricular cells to depolarize at an accelerated rate, which overrides sinus 
rhythm. Triggered activity refers to action potential generation when oscillations 
in transmembrane resting potential reach activation threshold. There are two 
forms of triggered activity: early or delayed afterdepolarization. Reentrant VT 
requires specific electrophysiological substrates, including unidirectional 
conduction, functional or structural conduction block, and a region of “slow 
 8 
conduction.” Reentrant VTs are often seen in structurally abnormal hearts due to 
ischemic or non-ischemic heart diseases. Ventricular scars consist of regions of 
dense fibrosis with collagen and fibroblasts. There are also surviving myocyte 
bundles overlying on the scars, which are called infarction boarder zone 2. The 
dense fibrosis creates conduction block for the formation of reentry circuit 3. The 
surviving myocytes form a common pathway or isthmus with slowed conduction 
though the scar. Therefore, functional or structural slowed conduction and 
conduction block set the stage for sustained reentry VT. Most scar-related 
reentrant VT is monomorphic since the reenty circuit is stable and pin to the 
infarction border zone of the scar. Although a single scar can support several 
different reentrant circuits, a patient with myocardial infarction can have 
different morphologies of monomorphic VT 4.   
Without cardioversion in time, VT will quickly degenerate to VF, which is driven 
by many turbulent wavelets and has a very dynamic and complex pattern of wave 
propagation. Transition from VT to VF is due to the increased heterogeneity in 
refractoriness of the cardiac tissue induced by acute ischemia or other chronic 
heart diseases. Several mechanisms have been proposed to explain the 
underlying dynamics of VF. One widely studied mechanism is multiple wavelets 
VF and is characterized by the presence of multiple self-sustained electrical 
wavelets. Another well-established hypothesis is mother rotor VF, in which VF is 
deemed to be driven by one predominant fast source of excitation 5, 6. Preexisting 
tissue heterogeneity plays an important role in both hypotheses.  
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Although VF is likely responsible for an overwhelming majority of SCDs, recent 
studies from ICD patients indicate that up to 90% of detected spontaneous 
episodes of ventricular arrhythmias are either VT or fast VT (FVT) 7. Therefore, in 
most instances, ICD therapy can be targeted to treat VT before it degenerates to 
VF. 
 
 
1.2 ICD Therapy for Ventricular Arrhythmias 
 
 
Over the past two decades, implantable cardioverter defibrillators (ICD) have 
become the standard of care for patients at risk for SCD. Multiple multicenter 
trials have demonstrated that ICD implantation is the most effective therapy for 
SCD 8-11. Despite the proven efficacy of ICDs in saving lives, at least three 
complications have been associated with high voltage shocks. Firstly, high voltage 
shocks produce substantial pain, which is often associated with anxiety, fear and 
depression, reduced quality of life 12.  Secondly, while the majority of ICD shocks 
are appropriate, studies estimate that approximately 20 percent of patients with 
ICDs may experience inappropriate shocks within about three years of implant in 
response to a non-lethal arrhythmia or electrical noise within the device system 
13, 14. Finally, we have shown that ICD shocks could induce myocardial damage via 
electroporation 15 evident from post-shock RV endocardial electrograms, which 
were linked with increased risk of heart failure and death 16. Sweeney et al 
 10 
demonstrated that ICD shocked patients have substantially higher ventricular 
arrhythmia episode burden and poorer survival compared with anti-tachycardia 
paced-only patients 17. These results indicate that exclusive reliance on high 
voltage shocks could degrade ICD survival benefit.  Therefore, lower energy 
strategies have been promoted to improve survival and quality of life in ICD 
patients.  Recent adoption of shock-reduction programming strategies, include 
lengthening the number of intervals to detect VF, using more sensitive 
supraventricular tachycardia (SVT) discriminators, and employing ATP reduced 
shocks by 17 to 28% 18.  However, these efforts to prevent the delivery of shocks 
with increased programming have not fully eliminated the need for high energy 
shocks to terminate VF or the problems of inappropriate shock delivery for SVTs.  
In addition, ICD malfunction has been problematic in the cardiac rhythm 
management field.  According a recent meta-analysis of industrial reports of 
implantable device malfunctions to the FDA from 1990-2002, ICD malfunction 
replacement rate is significantly higher than for pacemakers. A detailed 
breakdown of causes of malfunctions shows that high-voltage components, 
connectors, and circuits are mostly to blame for malfunctions: battery/capacitor 
(31.7%), charge circuit (17.4%), connector/header (9.3%), miscellaneous 
electrical (24.9%). The difference in reliability between pacemakers and ICDs 
appears to come primarily from high-voltage hardware components 19.  Thus an 
unmet need for low energy electrotherapy challenges current high-energy shock 
paradigm. 
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Treatments, depending on the severity of symptoms and degree of structural 
heart disease, usually combine medications, device implantation, and catheter 
ablation. Antiarrhythmic drugs have been disappointing.  Catheter ablation is 
used for treatment of VT/VF associated with cardiomyopathy as well as 
idiopathic VT in structurally normal heart. Focal sources of ventricular 
arrhythmogenesis are particularly targeted by ablative therapy. However, 
ablation is typically adopted as an adjunct to ICD therapy, because ablation often 
fails due to anatomically complex multiple reentrant circuits, harbored within 
midmyocardium.  
 
 
1.3 Atrial Arrhythmia 
  
Besides lethal ventricular arrhythmias, atrial fibrillation (AF) is the most 
common arrhythmias encountered in clinical medicine. In 1999, AF affects 
approximately 2.2 million adults in the United States 20 and is the most common 
sustained heart rhythm disturbance observed in clinical practice. In the same 
year, a total of 66,875 deaths with AF as a contributing cause occurred, and a 
total of 1,765,304 hospitalizations (137.1 per 1,000 Medicare enrollees) were 
reported among persons with AF in the Medicare population.  
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The mechanism of paroxysmal AF is a single or multiple ectopic foci localized 
usually around pulmonary veins 21. This type of AF could be cured by catheter 
ablation. However, in chronic AF, the prevailing theory for its mechanism is that 
multiple random wavelets of activation coexist to create a disorganized atrial 
excitation pattern 22. There is also a hypothesis that AF may be induced and 
maintained by several stable, self-sustained rotors generating exceedingly high 
frequency excitation, with fibrillation tissue conduction in atria 23. Moreover, 
after onset of AF, atrial electrophysiological properties changed with time and the 
threshold of inducing and sustaining the arrhythmia was lowered. This process 
explained AF progression by a process known as electrical remodeling. Other 
than electrical remodeling, AF also causes contractile remodeling and irreversible 
structural remodeling. Mechanical remodeling manifests as decreased atrial 
contractility, which stimulates the structural remodeling due to the remodeled 
enlarged atria 24. The remodeled atrium then becomes an electro-anatomical 
substrate to sustain AF by allowing more wavelets with smaller reentrant circuits 
with shorter wavelength due to shortening of refractoriness, slowing of 
conduction, and an increase in heterogeneity of atrial tissue properties. Different 
from ventricular tachy-arrhythmias, the autonomic nervous system has an 
important and crucial role in the genesis, maintenance and abruption of AF 25. 
This has been attributed to the heterogeneous distribution of vagal innervation 
throughout the atria, which increases spatial dispersion of refractory periods. 
Although many people live with AF for years, chronic atrial fibrillation is 
associated with an increased risk of death. AF can decrease the heart's pumping 
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ability by as much as 20 to 25 percent. Combined with a fast heart rate over a 
long period of time, AF can result in congestive heart failure and tachycardia-
related cardiomyopathy. It is also a major cardiac cause of stroke 26. AF requires 
pharmacological and/or electrical shocks to restore sinus rhythm. However, 
medication for this arrhythmia has limited effect, and has the potential for 
serious side-effects, including promoting ventricular arrhythmias. The external 
transthoracic cardioversion for AF involves high-voltage electric shocks, thus 
requiring costly hospitalization and anesthesia. Implantable atrial defibrillators 
have been previously developed but are not accepted by patients because the 
technology employed at that time required high voltage shocks, which exceeded 
the patients’ pain threshold.  
  
1.4 Defibrillation Waveforms 
 
In 1899, two physiologists Prevost and Batelli at University of Geneva discovered 
that they could defibrillate the heart by applying appropriate high current AC or 
DC shocks directly to the surface of the myocardium 27. In 1947, Claude Beck 
successfully performed the first case human internal defibrillation on a pulseless 
14-year old boy with exposed chest during surgery. His defibrillator used AC 
current directly from the wall socket in operating rooms 28. In 1939, Gurvich and 
Yuniev suggested using a single discharge from a capacitor to defibrillate VF in 
Soviet Union, thus first introduced DC shock for the purposes of defibrillation 29. 
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In the West, scientists and clinicians had been used AC shock for defibrillation 
until 1960s. In the United States, in 1962, Lown et al. reported their success in 
terminating VT with a single DC monophasic shock in nine patients 30.  
 
Gurvich was the first person who demonstrated the superiority of the biphasic 
waveform over the monophasic in dogs in 1967 31, while, John Schuder is the first 
person who studied and compared the monophasic and biphasic defibrillation 
waveforms in the West in 1980 32. Mirowski and his colleagues produced the first 
ICD which then was implanted in a patient at John Hopkins Hospital. Soon after, 
ATP was added to the device therapy. Later, Schuder 33 together with Ideker’s 34 
continuous work on optimization of biphasic waveform made the contemporary 
miniature ICD possible.  
 
Current state-of-the-art ICD therapy is based on low energy ATP followed by a 
high-energy shock with biphasic truncated exponential waveform.  Initial 
biphasic waveform design was based on the Gurvich waveform 35, 36, which was 
generated by an inductor-capacitor-resistor (LCR) circuit resulting in a damped 
sinusoidal waveform. The Gurvich waveform is widely used in transthoracic 
defibrillators, which can accommodate large inductors. However, implantable 
device size constraints led to adoption of truncated exponential waveforms with 
different characteristics 37. The truncated exponential waveform is generated by a 
capacitor and high-voltage switch (resistor-capacitor (RC) circuit). Both damped 
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sinusoidal and truncated exponential waveforms have been optimized by 
empirical studies varying characteristics of the first and second phases such as 
duration: the rise-time and decay of each phase, energy ratio and time delay 
between the two phases, etc. Properly optimized biphasic waveforms of both 
designs have been shown to significantly decrease the defibrillation threshold 38.  
However, truncated exponential waveform is the dominant approach in ICD 
therapy due to the size of capacitors and reliability with which a large amount of 
energy can be transferred from a battery to a capacitor and then to the heart. 
Capacitor-based design allows a reasonably sized device for implantation in the 
body.  
 
However, it appears that the existing waveforms were inspired primarily by the 
circuit designers, without detailed understanding of the biophysical mechanisms 
of defibrillation. From a physiologic standpoint, it is rather clear that the 
truncated exponential waveform is not the most efficient way to stimulate cardiac 
tissue. For example replacing truncated exponential descending waveform with 
an ascending waveform improves DFT by ~15-20% 39, 40. Such an improvement is 
incremental but still not enough to justify significant increase in complexity of 
the high-energy circuit, which is likely to contribute to malfunctions.  
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1.5 Scope and Procedure of the Dissertation 
 
 
In this dissertation, we explore mechanisms of sustained ventricular and atrial 
tachyarrhythmias and the mechanisms of defibrillation using the conventional 
high-voltage single shock. Through the use of novel fluorescent optical mapping 
techniques and several animal models of ventricular and atrial arrhythmias, we 
develop and validate several novel low-voltage defibrillation therapies for atrial 
and ventricular arrhythmias. Chapter 2 will first overview several important 
previous studies by several groups on mechanisms of arrhythmia maintenance 
and termination using mathematical and experimental models. A study on 
multiple monophasic shocks improving electrotherapy of ventricular tachycardia 
in rabbit model of chronic infarction is presented in Chapter 3. Ventricular 
arrhythmias and low-voltage defibrillation therapy are studied in a more 
clinically-relevent in vivo canine model of healing myocardial infarction in 
Chapter 4. Finally, Chapter 5 discusses a novel multi-stage low-energy 
defibrillation therapy for atrial fibrillation in in vivo canine hearts. 
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2  Defibrillation Therapy towards Lower 
Energy  
  
 
2.1 Virtual Electrode Polarization Theory 
 
When myocardium is exposed to electric field, transmembrane voltage of 
myocytes could be altered during the electric stimulus. Some area of the 
myocardium is depolarized, where the action potential duration and refractory 
period is prolonged; some area of the myocardium is hyperpolarized, where the 
action potential and the refractory period is shortened; while the transmembrane 
voltage of other area remains the same during shock. The depolarization effect is 
caused by virtual cathode. And the virtual anode leads to hyperpolarization.  
 
Electric stimuli affect the cardiac tissue through the mechanism of virtual 
electrode polarization (VEP). VEP patterns induced by a single monophasic and a 
single biphasic shock were measured and compared by Efimov 41. He discovered 
that a monophasic shock induced post-shock epicardial transmembrane 
polarization with a highly nonuniform polarity-dependent pattern. 
Depolarization (virtual cathode) occurred around the cathode electrode and 
 18 
hyperpolarization (virtual anode) appeared close to the anode electrode 41, 42. 
Figure 2.1 shows the three types of tissue responses through the VEP effect 
produced by the electric shock 43. 
 
 
 
Figure  2.1. Three  types  of  tissue  responses  to  virtual  electrode  polarization:  de‐e.Kcitation. prolongation, and re‐excitation. Maps of shock‐induced polarization and representative traces superimposed with control action potentials are shown. Shock was  applied  from  a  1‐cm  electrode  placed  in  the  left  ventricular  cavity.  Electrical activity was mapped  from  the  left  ventricular  epicardium. At  the  end of  a  +200‐V monoplumic  shock  (upper  map),  negative  polarization  produces  shortening  of action potential  duration  (upper  blue  trace), while  positive  polarization produced its prolongation (red trace). A stronger shock (+300 V) resulted in stronger negative polarization  with  .subsequent  re‐excitation  following  shock  withdrawal  (green trace).  (From  Efimov  et  al,  J  Cardiovasc  Electrophysiol,  Vol.  J  I,  pp.  339­353, March 
2000) 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Figure 2.2 The spatial pattern of polarization at the end of the shock produced by a monophasic  shock  (+100  V,  7th  ms  of  an  8‐ms  shock),  optimal  biphasic  shock (+100/‐50 V, 15th ms of 16‐ms shock), and nonoptimal biphasic shock (+100/‐200 V, 15th ms of 16‐ms shock). The area of recordings (11.5 mm311.5 mm) is shown by the  red  box.  Values  of  polarization  are  shown  relative  to  the  preshock transmembrane voltage, with red assigned to positive polarization, blue to negative polarization, and white to areas of no polarization. RA and LA indicate right and left atrium,  respectively;  BE,  bipolar  electrode.  (From  Efimov  et  al,  Circ.  Res. 
1998;82;918­925)  
 
Then he varied the leading voltage of the second phase of the biphasic shocks 
from 0% to 200% that of the first phase 44. The VEP pattern created by biphasic 
shocks with a second phase at below 20% leading-edge voltage of the first phase 
produced was similar to that of a monophasic shock. The VEP pattern produced 
by biphasic shocks with a second phase at above 70% leading-edge voltage of the 
first phase was similar to that of a monophasic shock with an opposite polarity. 
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Post-shock arrhythmias were induced by both of these waveforms. However, 
when the amplitudes of the second-phase were from 20% to 70% that of first-
phase, the biphasic shocks produced uniform VEPs around zero. This is because 
the second phase of the biphasic shock reverses the VEP pattern produced by the 
first phase of the shock. Examples of transmembrane voltages maps at the end of 
a monophasic shock and two biphasic shocks with different ratios of leading edge 
voltage of first phase to that of second phase are shown in Figure 2.2. 
 
 
The transmembrane voltage of myocardium can be represented in terms of 
phase. On the phase map, phase equals to +π where the upstroke of an action 
potential is being initiated, while phase equals to -π where the myocardium is 
fully repolarized, and the phase is ranged from -π to +π during an action 
potential. A phase singularity is defined as a point on the phase map that is 
surrounded by a region of activated area, a region of refractory area, and a region 
of excitable area. Efimov et al showed that shock-induced phase singularity as a 
mechanism of initiation of reentrant activity, thus a mechanism of defibrillation 
failure 44. The new waveform (‘Re-excitation’) could be generated at the boundary 
between a virtual cathode and a virtual anode when the transmembrane voltage 
gradient in these two regions are strong enough and the virtual anode is strong 
enough to fully restore the excitability of the myocardium, which is called ‘de-
excitation’ effect of the shock 45. New reentrant circuit could be initiated by the 
post-shock waveform, which leads to failure of defibrillation. VEP theory of 
defibrillation is the first theory of defibrillation that counts the de-excitation 
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effect of the shock into the mechanism of defibrillation success and failure.  
 
 
 
 
Figure  2.3  Creation  of  a  shock‐induced  phase  singularity.  Electrical  activity  was recorded  from  the  area  shown  in  Figure  1  by  the  red  box.  The  upper  left  panel shows  the polarization pattern at  the end of  a 1100/2200‐V biphasic  shock  (15th millisecond  of  16‐ms  shock),  which  resulted  in  a  single  extra  beat.  The  scale  is shown in millivolts, calibrated in the same manner described in Figure 1. The point of phase singularity is shown with the black circle. The upper middle panel shows a 5‐ms  isochronal  map,  which  depicts  the  initiation  of  the  postshock  spread  of activation. The map starts at the onset of the 8‐ms second phase of the shock (phase reversal).  The  lower  left  and  lower  right  panels  show  optical  recordings  from several  recording  sites  used  to  reconstruct  the  activation  maps:  the  eight  sites marked  with  a  red  arrow  correspond  to  the  lower  left  panel,  and  the  16  sites 
 22 
marked  with  a  blue  arrow  correspond  to  the  lower  right  panel.  The  upper  right panel shows a continuation of the reentrant activation that follows the middle panel. Reentrant activity  then self‐terminated, after encountering refractory  tissue  in  the lower right corner of the field of view (see lower right panel traces). (From Efimov et 
al, Circ. Res. 1998;82;918­925) 
 
 
Figure 2.3 shows a phase singularity that was created by a shock and a new post-
shock waveform was generated at the boundary of a virtual cathode and a virtual 
anode where has the largest spatial gradient of transmembrane potentials. Based 
on the phase singularity mechanism, the optimal defibrillation waveforms should 
produce uniform VEPs over the whole heart. And this explains why the 
conventional biphasic waveform is superior compared to the monophasic 
waveform in defibrillation of VF. 
 
As we mentioned earlier, deexcitation effect of the shock could generate new 
wave front propagating from the depolarized area to the excitable area. On the 
other hand, the stronger the virtual anode, the more hyperpolarized the 
myocardium, which means more sodium channels are available to be activated. 
The larger the number of recovered sodium channels, the faster the conduction 
velocity is in the area. Therefore, when the excitable region is activated by the 
new post-shock wave front generated by the VEP effect, strong deexcitation effect 
of the shock could cause fast conduction through the virtual anode region, where 
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the excitable gap in the new reentrant circuit is. Therefore, the excitable gap is 
quickly eliminated by the new wave front. The wave front will hit the refractory 
region ahead of the excitable gap then vanish, which leads to the success of 
defibrillation. From the discussion above, we conclude that we could use the VEP 
theory of defibrillation to study and explain the mechanism of defibrillation, as 
well as to develop novel waveforms with higher efficacy to achieve low-voltage 
defibrillation.  
    
2.2 A Mathematical Model of VEP Unpinning Theory  
 
The VEP pattern including polarization polarity and strength is determined by 
the “activating function”, 46 which takes into account the field strength of the 
electric stimuli and the conductive properties of the tissue. For a constant field 
stimuli, virtual electrode patterns are mainly affected by tissue heterogeneities, 47-
49 which are scars and other functional and anatomical sources of resistive 
heterogeneity. On the other hand, reentrant circuits are shown to be prone to 
anchor and to be sustained at functional and anatomical tissue heterogeneities, 
where have stronger shock-induced VEP than other normal myocardial areas. 
Therefore, a shock with relatively low amplitude will selectively generate VEP at 
the areas that provide the substrate for VT/VF. As we discussed in the last 
section, a new waveform could be generated at the boundary between virtual 
cathode to virtual anode, which is around the rotor of the reentrant circuit. 
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Therefore, VT/VF could be terminated with significantly lower energy as 
compared to conventional defibrillation, in which the whole heart has to be 
excited and synchronized by a high-voltage shock. 
 
Theoretical studies have shown that unpinning of anatomical reentry can be 
achieved by a field of 0.5 V/cm when the electric shock is applied at a proper time 
with respect to one VT cycle, in contrast to a field >5 V/cm required for high 
energy defibrillation 50, 51. Thus, a ~100-fold = (5V/cm/0.5V/cm)2 decrease in 
defibrillation energy can be potentially achieved. The basic concept of the 
proposed novel method of defibrillation is illustrated in Figure 2.4. The theory 
predicted that unpinning is possible only during a termination window.  
 
 
 
Figure 2.4. Mechanisms of unpinning of anatomical reentry by far‐field low energy shock. Left: Anatomical obstacle  (round hole) provides  the  substrate  for  stimulus‐induced hyper‐ and depolarization of cells located at the cathodal and anodal sides of  the  obstacle.  E  =  0.2  V/cm.  Such  VEP  has  been  shown  in  experiments. Middle: Properly  timed  stimulus  given  during  reentrant  activity  around  the  obstacle.  The shock  induces VEP  (40 ms) which  first breaks  the  rotating wave of excitation and then causes its unpinning (360 ms). Right: Unpinning electric field E versus phase of reentry demonstrating existence of termination window. Termination field outside 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the window >10V/cm.   
2.3 Mechanisms of Termination of Ventricular 
Tachycardia in an in vitro Acute Model of Infarction 
Border Zone 
  
Preliminary experiments to assess the new unpinning theory of defibrillation by 
our group were first conducted by Ripplinger et al 52 in superfused rabbit right 
ventricular (RV) free wall preparations (n = 14). The survival of 50-200 µm thick 
endocardial layer was verified by phospho-Connexin43 immunohistochemistry. 
Reentrant arrhythmias were initiated by burst pacing at an interval of 100-130 
ms. Reentry was easily inducible and sustained in all preparations. The number 
of sites of anchoring varied from 2 to 8 in various preparations. Monophasic 
shocks (10 ms, 0.1-2.1 V/cm) were applied parallel to the endocardium from two 
parallel mesh electrodes located in the bath. Time of shock application was varied 
throughout the reentrant cycle with circuitry that modulated the time delay based 
on a bipolar ECG recording.  
 
Optical mapping of electrical activity in these preparations revealed that shocks 
applied during the appropriate phase of the reentrant cycle depolarized a region 
near the core of reentry. This area of depolarization serves as a secondary source 
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and then creates a new wave front which collides with and annihilates the 
reentrant arrhythmia, exactly as predicted in theoretical studies shown in Figure 
2.4. An example of termination of reentry by this mechanism is shown in Figure 
2.5. In these experiments, a total of 192 reentries were initiated and terminated in 
14 in vitro rabbit preparations. Reentries were unpinned/terminated at 
E80=1.21±0.2V/cm (field at 80% probability of termination). This is 6.6-fold the 
average field excitation threshold. All reentries were terminated at or below 2.1 
V/cm. Conventional defibrillation is achieved at E80 = 5.4±0.8 V/cm.40 Thus, the 
data suggest that a ~20-fold energy improvement (5.4V/cm/1.21V/cm)2 could be 
achieved in comparison to conventional incremental improvements in high 
energy defibrillation by 10-30% with the introduction of a new waveform or lead. 
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Fig. 2.5. Mechanisms of successful unpinning of anatomical reentry. A: preparation photograph  showing optical  imaging  field of  view  (solid black  square),  location of reentry core (identified as a stationary line of block/ trajectory of PS), and outline of phase‐plane maps  (dashed black  line). Monomorphic  ventricular  tachycardia  (VT) was maintained by counterclockwise reentry rotating around the line of block. We imaged  the  entire  ventricular  preparation.  Tissue  above  the  field  of  view  is  atrial and  did  not  have  any  communication  with  ventricular  preparation.  B:  VEP  map showing positive and negative polarization near the line of block/core of reentry as in Fig. 4. C: optical trace (blue) from site shown with white box in D,1–7. This trace can be used as a reference to compare the timing of the shock between Figs. 5 and 6. VT was terminated by a 0.58 V/cm shock (red trace). D: mechanisms of termination (1–7)  show  instantaneous  phase  distributions  at  time  instants  marked  in  C.  The unpinning  pulse  created  a  VEP‐induced  secondary  source  of  excitation  (D,2,  red 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arrows) that merged with the reentrant wave (D,3), detaching it from the core. This unpinned wavefront terminated on reaching the preparation edge. A remnant of the wave  induced  by  the  VEP  continued  to  propagate  counterclockwise  and  self‐terminated at  a  refractory area  (D,5–7).  (From Ripplinger  et  al, Am  J Physiol Heart 
Circ Physiol 291: H184–H192, 2006.)   
  
2.4 Mechanisms of Termination of Ventricular 
Tachycardia in Rabbit Heart with Chronic Infarction 
  Arrhythmias are shown to be induced with significantly higher likelihood and 
reproducibility in a model of the acute phase of infarction, in as compared to 
coronary perfused preparations or intact hearts. However, many sustained 
ventricular tachycardia are related with chronic myocardial infarctions and scars 
in the clinical setting. It remains to be shown that arrhythmias could be 
reproducibly mapped in intact hearts with chronic healed infarct.  
 
Our group has previously conducted a preliminary study in a rabbit model of 
healed infarction 53, which fully supports our hypothesis. In this model, infarction 
was induced by ligature of the left marginal artery. Animals were allowed to 
recover for 6-14 weeks prior to the study. Ripplinger et al 54 studied the 
mechanism of induction and termination of ventricular arrhythmia in this model 
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using panoramic optical mapping technique. As shown in Figure 2.6, crowded 
isochromes in activation maps were observed during sinus rhythm and RV 
endocardial pacing at surviving endocardial infarction border zone, which is 
typical in this rabbit model of chronic infarction.  
 
 
 
Figure 2.6 Characteristics of a  typical chronic MI rabbit heart. A, B: Heart surface 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and corresponding 2D projection activation maps during RV pacing. The solid white 
line indicates the septum. The dashed white line indicates the infarct region. Asterisks indicate  the  infarct  region  from which  signals  in  panel H  correspond. C, D: Heart surface  and  corresponding 2D projection  activation maps during  sinus  rhythm. E: Masson  trichrome  histology  of  short  axis  slices  from  apex  to  base.  Scar  tissue  in infarct region is blue. F: Photograph of anterior view of heart. Infarct region is white tissue  near  apex. G: High  resolution  histology  image  corresponding  to  red  box  in panel E. The red arrows  indicate  thin  layer of  surviving endocardial BZ. G: Optical action potentials (Vm) and dVm/dt from locations indicated with asterisks in panels 
A and B during RV  endocardial  pacing. A black  dot  indicates  dVm/dtmax on  each signal. (From Ripplinger et al, Heart Rhythm 2009;6:87–97)    
All the shocks in this study were delivered from two mesh electrodes parallel to 
each other located in the Langendorff perfusion chamber, with one facing the 
right ventricle and the other facing the left ventricle. The distance between two 
mesh electrodes was 10 cm. The VEP patterns generated by 5 V/cm shocks with 
opposite polarities are shown in Figure 2.7. Consistent with our previous finding, 
the VEP pattern of a monophasic shock is nonuniform, polarity-dependent. And 
it is slightly modulated by tissue heterogeneity, which is represented by the 
infarction and the infarction border zone in this model. The main mechanism of 
sustained ventricular arrhythmia is monomorphic ventricular tachycardia with 
cycle length of 174.7 ± 38.4 ms, maintained by a single mother rotor mainly 
located at the infarction border zone. , 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Figure 2.7. Shock‐induced VEP. A: Photograph of anterior view of heart. The infarct region is indicated with a dashed white line. B: Heart surface and corresponding 2D projection of shock‐induced VEP for a 5 V/cm LV shock. White solid and dashed lines indicate  septum  and  infarct  region,  respectively.  C:  Optical  action  potentials showing  positive  and  negative  shock‐induced  polarization  overlaid  onto  control action potentials. Time of shock  is  indicated with dashed  lines. Locations of optical action potentials are indicated with asterisks on 2D projections in panels B and D. 
D: Heart  surface  and  corresponding  2D  projection  of  shock‐induced  VEP  for  a  5 V/cm RV shock. E: Optical action potential from location indicated with a white “x” in 2D map of panel F showing time of earliest postshock activation, which resulted in  one  shock‐induced  extra  beat.  Time  of  shock  is  indicated with  dashed  lines.  F: Heart  surface  and  corresponding  2D  projection  activation  maps  of  postshock activation sequence. (From Ripplinger et al, Heart Rhythm 2009;6:87–97) 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Anti-tachycardia pacing (ATP) was shown ineffective in this model. The 
cardioversion threshold (CVT) of a single shock was measured for coupling 
intervals of approximately 0%, 20%, 40%, 60%, and 80% that of the VT cycle 
length. It was found that the minimum and maximum CVT for a same VT 
morphology was significantly different when the shock was applied at different 
coupling interval of a single VT cycle length. The CVTs at the favorable versus 
unfavorable phase for each animal were determined and were found to be 7.75 ± 
1.89 V/cm versus 4.13 ± 1.55 V/cm (P = 0.005).  
 
Figure 2.8 shows an example of successful cardioversion of a sustained reentry 
VT by a single monophasic shock applied at the favorable phase with strength of 
3 V/cm. The shock-induced secondary source (virtual cathodes) generated new 
wave fronts that propagated at the direction opposite to the reentrant wave front 
and collided with the reentrant wave front. The excitable gap in the reentrant 
circuit was completely eliminated. Therefore, the reentry was unpinned from its 
anchoring site and the arrhythmia was terminated successfully.  
 
However, this favorable phase or optimal termination window with significantly 
lower CVT compared to the unfavorable phases was different for each VT 
morphology, and varied with different hearts. It also depends on the size and 
location of the infarct, the size and location of the defibrillation electrodes, the 
reentrant circuit, etc. It is impossible for us to measure this favorable phase 
clinically for individual patient. This explains that why a single monophasic shock 
cardioversion requires high energy. And more importantly, new waveforms needs 
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to be developed in order to achieve low-voltage cardioversion of VT. 
 
  
Figure  2.8.  Termination  of  VT  by  a  shock  applied  at  the  correct  phase.  A: Photographs and heart surface phase maps of anterior and posterior views of heart. 
Dashed white lines correspond to infarct region. The solid white line corresponds to septum.  The  dashed  green  line  in  posterior  view  corresponds  to  where  the  heart surface  map  was  cut  and  unwrapped  to  produce  the  2D  projection  maps.  Heart surface phase maps correspond to t = 0 ms. B: 2D projection phase maps from time t = 0 to t = 440 ms. One complete rotation of VT can be observed from t = 0 to t = 236 ms.  At  t  =  238  ms,  a  3  V/cm  shock  is  applied  that  terminates  VT.  Asterisks  and 
arrows  indicate  shock‐induced  secondary  sources  of  excitation.  C:  Optical  action potential  (black)  showing  time  of  shock  application  (red).  (From  Ripplinger  et  al, 
Heart Rhythm 2009;6:87–97) 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3  Multiple Monophasic Shocks Improve 
Electrotherapy of Ventricular Tachycardia in a 
Rabbit Model of Chronic Infarction 
 
 
3.1 Abstract 
 
Background: Previously, we showed that the cardioversion threshold (CVT) for 
ventricular tachycardia (VT) is phase-dependent, when a monophasic shock 
(1MP) is used. In this study, we aimed to extend these findings to a biphasic 
shock (1BP), and to compare efficacy of phase-independent multiple monophasic 
(5MP) and biphasic shocks (5BP). 
Methods: Panoramic optical mapping with Blebbistatin (5 μM) was performed in 
post-MI rabbit hearts (n = 8). Flecainide (1.64 ± 0.68 μM) was administered to 
promote sustained arrhythmias. 5MP and 5BP were applied within one VT cycle 
length (CL). Results were compared to 1BP and antitachycardia pacing (ATP). 
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Results: We observed monomorphic VT with CL = 149.6 ± 18.0 ms. Similar to 
1MP, CVTs of 1BP were found to be phase-dependent and the max vs. min CVT 
was 8.6 ± 1.7 vs. 3.7 ± 1.9 V/cm, respectively (p = 0.0013). Efficacy of 5MP was 
higher than 1BP and 5BP. CVT was 3.2 ± 1.4 vs. 5.3 ± 1.9 V/cm, for 5MP vs. 5BP, 
respectively (p = 0.00027). 5MP vs. averaged 1BP CVT was 3.6 ± 2.1 vs. 6.8 ± 1.5 
V/cm, respectively (p = 0.00024). ATP was found completely ineffective in this 
model. 
Conclusions: Maintenance of shock-induced virtual electrode polarization (VEP) 
by multiple monophasic shocks over a VT cycle is responsible for unpinning of 
reentry leading to self-termination. Elimination of VEP by shock polarity reversal 
during multiple biphasic shocks proved ineffective. A significant reduction in 
CVT may be achieved by applying multiple monophasic shocks within one VT CL 
or one single shock at the proper coupling interval.  
 
3.2 Keywords 
 
Ventricular tachycardia; Cardioversion; Optical mapping; Infarction 
 
3.3 Introduction 
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Prior myocardial infarction (MI) is manifest in 75% of victims.55, 56 The most 
common event leading to SCD is ventricular tachycardia (VT) degenerating into 
ventricular fibrillation (VF). Sustained VT in patients with chronic MI is 
predominately found to be monomorphic VT, which is caused by stable reentry.57, 
58 The mechanism of reentry in ischemic heart disease relates to electrical 
remodeling at the infarct border zone (IBZ) which refers to the region of 
functioning myocytes at the edge of myocardial scars, which is characterized by 
slow and more heterogeneous conduction properties.59-61 
 
The risk of arrhythmic death is found to be higher than that of non-arrhythmic 
death in patients over a two-year period after MI.62 Radiofrequency catheter 
ablation is successfully used to interrupt the reentrant circuit. But there are risks 
associated when the patient has to remain in VT for a relatively long period of 
time required for the selection of ablation sites. Moreover, VT of other 
morphologies may reoccur and cause SCD even if the ablation procedure was 
successful.58, 63, 64 ICD therapy, which is now used as the primary treatment in 
patients with serious ventricular arrhythmias, has higher efficacy than 
antiarrhythmic drug therapy in preventing SCD in high-risk post-MI patients.65-68 
Therefore, the defibrillation therapy for post-MI patients deserves further studies 
and improvements, especially in the model of chronic MI. 
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Previously, we have shown that the CVTs of a single monophasic shock (1MP) for 
sustained VT, in a model of isolated rabbit RV preparations with acute MI and in 
the intact rabbit hearts with chronic MI, depend on the VT cycle length (CL) and 
the coupling interval of the cardioversion shock.52, 54  
 
The goals of this study are: 1) to provide deeper insights into mechanisms of 
arrhythmia and cardioversion in the rabbit model of chronic MI; 2) to explore 
whether the CVTs of a single biphasic shock (1BP) for sustained VT are also 
phase-dependent; and 3) to compare the efficacy of phase-independent multiple 
monophasic and biphasic shocks in this infarct rabbit model.  
 
3.4  Materials and Methods 
 
3.4.1   Survival Surgery 
 
The experimental protocol was approved by the Institutional Animal Care and 
Use Committee of Washington University. Nine New Zealand White rabbits of 
either sex were used in this study. The infarction was created by left coronary 
ligation during in vivo survival surgery as previously described.53 One rabbit died 
of congestive heart failure and subsequent pulmonary effusion 10 days after the 
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surgery. Therefore, eight rabbits with chronic MI were used for in vitro 
experiments. 
 
3.4.2   Heart Preparation 
 
Rabbits were allowed to heal for an average of 102 ± 41 days before acute optical 
mapping experiments. Rabbits were injected intravenously with sodium 
pentobarbital (50 mg/kg) and 1000-2000 U heparin and the heart was removed 
Langendorff-perfused and optically mapped as previously described.41 To 
eliminate the motion artifacts in optical recordings, we used Blebbistatin (5mM, 
BB; Fisher Scientific, Fair Lawn, NJ).69  
 
3.4.3   Acute Experimental Protocol 
 
Imaging was performed using a panoramic imaging system as previously 
described.70, 71  Flecainide was used to promote sustained (lasting more than 3 
minutes) ventricular arrhythmias in rabbit hearts. A dose of flecainide started 
with 0.5μM and was increased at a step of 0.5μM until sustained ventricular 
arrhythmia could be induced by burst pacing or a multiple shock protocol (4 
pulses, 5 V/cm, 130-170 ms coupling interval). For the same VT morphology, five 
monophasic shocks (5MP) with duration of 10 ms and five biphasic shocks (5BP) 
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with durations of 6 ms for the first phase and 4 ms for the second phase were 
applied within one VT CL. The ratio between the 1st and 2nd phase leading edge 
voltages was 2:1. Besides 5MP and 5BP, 1BP was also applied at various phases 
throughout one CL for the same VT morphology. All the cardioversion shocks 
were applied from two external stainless steel mesh electrodes, which were 
configured and connected to the pulse generator as previously described.54 CVTs 
were determined for each shock waveform. Antitachycardia pacing (ATP, 8 
pulses, 88% of VT CL) was applied in 6 hearts, 6 trials per heart. 
 
3.4.4   Data Analysis 
 
A 3D geometry of the heart was reconstructed and optical signals were registered 
with the epicardial surface as previously described.70, 71 The epicardial geometry 
is represented by spherical coordinates (θ, φ, r), where (θi, φi) is an evenly spaced 
grid, which can be easily redrawn on a 2D plane. A 2D unwrapped epicardium 
map is shown in the middle panel of Figure 3.1. Although unwrapping the 3D 
geometry to a 2D plane causes distortion at the apex, the 2D grid is very useful in 
calculating and visualizing epicardial data for which the analyses do not involve 
distance between data points, for example, the calculation of phase maps. In all 
2D unwrapped maps the anterior septum is located in the middle. 
 
 40 
CVTs of different shock waveforms were compared. Comparisons of each pair 
were made for the same VT morphology and then averaged for all the 
morphologies. A paired Student’s t-test was used, and p < 0.05 was considered 
statistically different. 
 
3.5 Results 
 
3.5.1   Initiation of sustained ventricular arrhythmias 
 
Sustained VT could not be induced in this model by either multiple plateau-phase 
shocks or burst pacing. All induced ventricular arrhythmias were short-lived 
meandering rotors that self-terminated within several seconds. Therefore, we 
used flecainide (1.64 ± 0.68 μM) to promote sustained VT. The effective 
refractory period (ERP) was 183 ± 11 ms before administration of flecainide, and 
increased to198 ± 15 ms thirty minutes after administration of flecainide 
(p=0.0005).  
 
Multiple shocks (CL=125-160ms) were the most effective way to induce VT. 
Figure 3.1 shows a representative example of initiation of VT by the multiple 
shocks. The first shock was applied following 1 minute of continuous pacing 
(CL=300ms). The VEP pattern of 1MP (5 V/cm) is shown in Figure 3.1, the 
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rightmost one in the middle panel. The first activation map in Figure 3.1 shows 
the epicardial activation sequence after a diastolic field excitation. In the first 
activation map, the depolarized region was excited first. The wave front spread 
across the apex toward the base of the heart and excited the hyperpolarized area. 
A counterclockwise reentry close to the infarct region is observed in activation 
map 2 and 3. A new wave front was induced by the last shock in activation map 4. 
After the shock sequence, a clockwise reentry meandered for a short time and 
then stabilized at the IBZ forming a mother rotor (See activation map 5 and 6).  
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Figure 3.1: Initiation of a stable VT by multiple shock protocol. Top: Optical signal (purple) showing that a VT was  induced by four monophasic shocks (red, 5 V/cm, 163  ms  between  each  shock).  Numbers  1‐6  correspond  to  the  time  windows  of activation maps  1‐6  in  the  lower  panels,  respectively. Mid:  Left  panel  is  a  digital photograph  of  the  anterior  view  of  the  heart.  Middle  panel  is  the  2D  unwrapped epicardium map.  The  solid  line  represents  the  septum.  Infarct  region  is  indicated with a dashed line. Right panel is a 2D unwrapped map of shock‐induced VEP for a 5 V/cm  1MP.  Bottom:  Six  successive  activation  maps  show  the  process  of  the initiation  of  a  stable  reentrant  circuit.  Left  column  shows  anterior  view  of  3D activation maps. Right column contains 2D unwrapped activation maps.  
 
3.5.2   Mechanism of sustained ventricular arrhythmia in 
CMI   
A total of 95 sustained VTs were induced in 8 hearts. They were monomorphic 
VTs with CL=149.6±18.0ms. We identified 28 different ECG morphologies of VT 
(3.5±0.9 VT morphologies per heart). A mother rotor, anchored to the infarct 
region, was the primary mechanism of sustained VT in 89% (25 of 28) 
morphologies. Figure 3.2 shows phase maps and Lead I ECG recordings of two 
main VT morphologies (56% inductions for the clockwise reentry and 22% 
inductions for the counterclockwise, respectively) in a representative heart. 
Similar patterns were observed in all hearts.  
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Figure  3.2:  Two  main  morphologies  of  sustained  stable  VT  in  one  heart.  A. Photograph of anterior view of heart. Infarct region is white tissue from mid LV to apex. B. 3D phase maps of stable reentrant VTs rotated clockwise and anchored at IBZ. C. Lead I ECG during clockwise VT. This was the predominant VT morphology which appears at 56% inductions. The small peak which appeared every three beats indicates 3:1 retrograde excitation of atria during VT. D­F. Similar panels as A,B, and C only for a second primary VT morphology (22% inductions) which was counter‐clockwise.   
3.5.3   Efficacy of Antitachycardia Pacing (ATP)  
All ATP trials failed to terminate the sustained VT. 
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3.5.4   Termination of sustained VT by a single biphasic 
shock  
Figure 3.3 shows an example of 1BP applied at an appropriate phase, and 
terminated a sustained stable VT after three post-shock extra beats. The shock, 
with an amplitude of 4 V/cm, was applied at t=160ms when the reentry wave 
front just arrived at the apex. The shock-induced secondary source generated a 
new wave front propagating in the direction opposite to the reentry wave front. 
The excitable gap in the reentry circuit was completely eliminated, and the 
reentry detached from the IBZ anchoring site.  After the unpinning of the reentry, 
the arrhythmia meandered for three extra beats and then self terminated. 
 
Figure 3.4 shows an example of cardioversion failure, when the shock was 
applied at the inappropriate phase of the reentry. As shown in the phase map at 
t=264, a shock, with a strength of 4 V/cm, was applied when the reentry wave 
front spread most of the right ventricle, and was about to turn around toward the 
left ventricle. The posterior and lateral RV base was excited simultaneously by the 
shock-induced VEP effect and the reentry wave front. However, there existed a 
large excitable area in the clockwise propagation direction of the reentry wave 
front, at the anterior RV base, after the shock at t=276 ms. Moreover, the greater 
refractory area in front of the reentry wave front at t=320 ms, compared to the 
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same phase of VT at t=40 ms, became fully excitable at t=360 ms. Therefore, the 
reentry persisted and the shock failed. 
 
 
 
Figure 3.3. Termination of stable VT by 1BP applied at the proper phase. Heart and VT morphology correspond to Figure 3.1 and 2. Top: Optical action potential (blue) shows that VT terminated after 1BP (red, 4 V/cm, t=160 ms). Lower panels are 2D wrapped  phase  maps  from  t=0  to  t=780  ms.  Asterisks  indicate  shock‐induced secondary sources. Arrows represent the directions of the wave front propagation. 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Figure 3.4.  Failure  of  cardioversion due  to  the  improper  application  time of 1BP. This VT had the same morphology as that in Figure 3.3. Top: Optical action potential (blue)  shows  the  cardioversion  failure  of  a  1BP  (red,  4  V/cm,  t=266 ms).  Lower panels are 2D wrapped phase maps.   
Figure 3.5 shows an example that an inappropriate application time requires a 
higher CVT. As shown in the phase map at t=280 ms, the shock with a strength of 
8 V/cm is applied at the same phase of reentry as that in Figure 3.4. In the phase 
map at t=291 ms right after the shock, we observe two regions, which were 
effected by the shock-induced VEP. Besides the depolarized region (red), there is 
a hyperpolarized region (blue) at the anterior LV and RV base. A faster 
conduction occurred in this example, compared to the one shown in Figure 3.4, 
because a stronger shock produces deeper deexcitation.43 Therefore, the rapid 
propagation through the excitable regions, which is shown in the phase map at 
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t=300 ms, led to the elimination of excitable gaps soon after the shock and 
therefore a successful unpinning. The arrhythmia self-terminated after 
meandering for two extra beats. 
 
Figure  3.5.    Termination  of  stable  VT  with  improper  application  time  of cardioversion shock requires higher energy. This VT had  the same morphology as previous  figures.  Top:  Optical  action  potential  (blue)  showing  that  VT  was terminated by 1 BP shock (red, 8 V/cm, t=281 ms). Lower panels are 2D wrapped phase maps. 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Figure 3.6 shows a representative plot of coupling intervals versus CVTs of 1BP 
for one VT morphology, after recalculating the actual shock application time and 
the exact VT CL. In this example, the minimum CVT is 5 V/cm at 29%, while the 
maximum CVT for this VT morphology is more than 10 V/cm since the shock 
strength of 10 V/cm failed at 4% of CL. This difference in CVTs is significant in all 
eight hearts, where the maximum vs. minimum CVT of 1BP applied at various 
phases was 8.6 ± 1.7 vs. 3.7 ± 1.9 V/cm, respectively (p=0.0013). Therefore, 
similar to our previous results on 1MP, the CVTs of 1BP are phase-dependent and 
the appropriate time of shock (reentry vulnerability window) varies with the VT 
morphology.  
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Figure 3.6. Plot of the application phases of the shock versus CVTs with 1BP for the VTs with a same morphology. The application phase varied within one VT CL. Shock strength started with 1 V/cm and was increased by 1 V/cm until VT was terminated or the shock strength reached the maximum amplitude we could deliver (10 V/cm). The CVT varied greatly as a function of the application phase. 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3.5.5   Termination of sustained VT by five monophasic and 
five biphasic shocks  
Due to the phase-dependent efficacy of both 1MP and 1BP, successive multiple 
pulses within one VT CL were explored. We used five pulses in order to cover the 
whole phase grid which we scanned separately with one single shock.  In eight 
infarcted hearts, the CVT of 5MP versus 5BP was 3.2 ± 1.4 vs. 5.3 ± 1.9 V/cm, 
respectively (p=0.00027).  
 
Figure 3.7 shows the application of 5MP with strength of 4 V/cm terminated a 
stable reentrant VT after one post-shock beat. The phase maps from 0 to 120 ms 
show a nearly complete VT reentry. As shown in the phase map at t=190 ms, the 
depolarized region (red) consumed part of the excitable gap.  The remaining four 
shocks provided additional depolarization of already depolarized myocardium in 
this region via VEP effect. Therefore, the clockwise reentry wave front was halted 
when it propagated to the refractory area at t=264 ms, and the wave front 
vanished at t=280 ms after the fourth shock.   
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Figure 3.7. Termination of VT by 5MP applied within one VT CL. Top: Optical action potential (blue) shows that VT unpinned and self‐terminated after application of 5MP (red, 4 V/cm, t=177 ms). The first panel below the optical trace is a VEP map measured from a 1MP shock (5V/cm) applied at the plateau‐phase. The other panels are 2D unwrapped phase maps.  
Figure 3.8 shows an example of a reentrant VT destabilized by the application of 
5BP with strength of 5 V/cm. The first biphasic shock excited part of RV, as 
shown in the phase map at t=224 ms. The following four shocks prolonged the 
refractory period of the same area, which was excited by the first shock. After the 
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last shock, the clockwise wave front encountered the refractory region and the 
reentry circuit was disrupted and destabilized. However, this arrhythmia self-
terminated after meandering for approximately one minute beyond the 
administration of the shocks, unlike the one shown in Figure 3.7.  
 
For all the VT morphologies, a maximum CVT of 1BP is higher than that of 5MP: 
8.8 ± 1.2 vs. 3.2 ± 1.2 V/cm, respectively (p=0.00001). Interestingly, 5MP has 
nearly a two-fold lower CVT than averaged 1BP CVT at 3.6 ± 2.1 vs. 6.8 ± 1.5 
V/cm, respectively (p=0.00024). Meanwhile, CVT of 5MP is similar to the 
minimum CVT of 1BP at 4.3 ± 1.9 vs. 4.9 ± 2.7 V/cm, respectively (p=0.37).  
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Figure 3.8. Destabilization of stable VT by 5BP. Top: Optical action potential (blue) shows  that VT was destabilized  after  application of  5BP  (red,  5 V/cm,  t=213 ms). Lower panels are 2D wrapped phase maps. Termination of this VT was not recorded in this file. However, it self‐terminated after approximately one minute. 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3.6 Discussion 
 
In this study, we have demonstrated that (1) in accordance with our previous 
studies on 1MP, 1BP has a strong phase-dependent efficacy in terminating 
monomorphic VT. 52, 54; (2) an application of 5MP during one cycle of VT may 
offer a novel approach to cardioversion, which is not phase dependent; (3) in 
contrast to single shock cardioversion, a 5-pulse cardioversion approach is more 
efficacious with monophasic shocks compared to biphasic shocks; (4) ATP, 
applied from RV endocardium, is not efficacious in this model of VT.  
 
The evolution of defibrillation therapy from its initial discovery by Prevost and 
Bettelli included significant work on optimization of the defibrillation 
waveform.27 The original study of Prevost and Battelli reported the possibility of 
defibrillation by both alternating current (AC) and capacitor discharge energy 
delivery. However, during the 1st half of the 20th century, defibrillation studies 
were primarily focused on AC defibrillation, including seminal reports on the first 
clinical defibrillation in open heart and closed chest configurations.28, 72 Gurvich 
was the first to demonstrate significantly higher efficacy of DC defibrillation as 
compared to AC, including first monophasic and then biphasic shocks.29, 73 
Following his lead during the second half of the 20th century, defibrillation 
therapy evolution focused on DC shock defibrillation by optimizing the biphasic 
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waveform. Yet, multiple pulse electrotherapies remained under investigation in 
basic electrophysiology laboratories.74 Success of this approach is evident from 
the widespread application of antitachycardia pacing for treatment of VT.   
 
In clinical trials, ATP has been approved in order to terminate 90% of 
spontaneous VT with a CL longer than 300 ms.75-77 Wathen MS et al applied 1~3 
ATP trains to fast VTs which are defined by a CL 240-320 ms, and successfully 
terminated 84% of episodes with mean CL 280-320 ms versus 69% of episodes 
with mean CL 240-280 ms.7 However, in this study, ATP applied from RV 
endocardium did not terminate the sustained monomorphic VT. Thus, the 
efficacy of termination of VT by ATP may well depend on the nature of VT; for 
example, the VT CL, the conduction velocity, and the methods used to initiate 
VTs. Besides, the location of the pacing electrode, with respect to the 
myocardium infarct may also affect the success rate of this therapy.78  
 
Sustained VT could not be induced, in all eight rabbit hearts with chronic 
myocardium infarct, without the administration of Flecainide (1.64 ± 0.68 μM), 
which is a class IC anti-arrhythmic drug. Flecainide has been shown to have 
significant ventricular proarrhythmic effects, such as converting unsustained VT 
to sustained VT, by decreasing both the longitudinal and transverse conduction 
velocity of ventricular myocardium without blocking the central common 
pathway in healing infarcts.79, 80 In this study, 95 sustained ventricular 
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arrhythmias were monomorphic VT, 89% of which are observed to be rotors 
anchored to IBZ. We also observed shock-induced polymorphic VT whose rotor 
kept meandering until it self-terminated before achieving stabilization at IBZ. 
Flecainide slowed the conduction and shortened wavelength, which allowed 
circus movement in the dimension of rabbit heart.  Ischemia or hypoxia in 
patients also promotes arrhythmia by reducing the conduction velocity. 
Therefore, the model in this study can be used to further understand the 
mechanism of initiation and termination of VT in the patient with myocardium 
infarct under the condition of ischemia and/or hypoxia. 
 
We observed the same phase-dependency of 1BP as 1MP in termination of 
monomorphic VT in this model. 1BP applied at the appropriate phase could 
successfully unpin the VT reentry with relatively low shock strength by creating a 
new post-shock wave front that activates all the excitable gaps in the loop ahead 
of the reentry wave front.  Consequently, the VT self-terminated after several 
extra beats (Figure 3.3). For 1BP applied at an inappropriate phase, it fails 
because it could not eliminate all the excitable gaps (Figure 3.4).  It could also fail 
by changing the VT morphology instead of terminating it. However, with higher 
shock strength, an improperly-timed biphasic shock could unpin reentry by 
causing rapid propagation through newly excitable regions, which results in the 
elimination of excitable gaps and successful cardioversion (Figure 3.5). 
Therefore, elimination of the excitable gap by shock-induced depolarization 
(Figure 3.3) or hyperpolarization (Figure 3.5) is a crucial way to interrupt the 
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reentrant circuit as well as the main mechanism of cardioversion for this model. 
Since the shock-induced VEP pattern is settled, if we could sense the reentry 
wave front and apply the shock before the reentry wave front reaches the 
depolarized region of the VEP, reentry can be terminated with lower shock 
strengths. 
 
In our previous study, the maximum and minimum of 1MP applied at different 
phases of VT were found to be: 7.75 ± 1.89 V/cm versus 4.13 ± 1.55 V/cm, 
p=0.005.54 We would like to compare the cardioversion efficacy between 1MP 
and 1BP in this study. However, each experiment already lasts 8~10 hours 
without including the 1MP protocol. Moreover, our animal model is exactly the 
same as the previous study. Therefore, we can rely on the results from the 
previous study, which suggest that 1BP has a similar efficacy with 1MP.  
 
Due to the phase-dependency of 1MP and 1BP, we studied the phase-independent 
multiple pulses. We found that multiple pulses unpinned reentry VT by 
maintaining the shock-induced depolarization effect, which sustained the tissue 
refractory until the reentry wave front was annihilated. The CVT of 5MP was 
approximately one half lower than that of 5BP. This is because the sequential 
multiple monophasic pulses reinforce the shock-induced VEP effect, which could 
keep the tissue refractory. In contrast, the second phase of the biphasic shocks 
reverses the VEP effect of the first phase and prevents maintenance of the 
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secondary source. Therefore, after comparison among 1BP, 1MP, 5BP, and 5MP, 
we found that 5MP was phase-independent and the most efficient waveform for 
the low-voltage cardioversion of the rabbit heart with MI. 
 
3.6 Study Limitations 
 
In order to optically record the electric activity on the surface of the heart and to 
register the optical recordings to the myocardium, we have to use the excitation-
contraction uncoupler, Blebbistatin. This agent frees up adenosine 
triphosphate that would be used by contraction and thus improves metabolic 
state of the heart including possible protection against arrhythmia.  
 
Our fluorescence optical mapping system only allows us to study the action 
potentials from epicardium. The electric activity of septum and endocardium 
cannot be mapped. Therefore, those intramural reentry circuit or post-shock 
breakthrough cannot be explored in this study.  
 
In order to panoramically map the whole ventricular surface of the rabbit heart, 
the spatial resolution is reduced to approximately 1.7 x 1.7 mm2, which is 
relatively low with respect to the size of a single myocardial cell. Each channel of 
photodiode array also collects optical signal scattered from neighboring tissues 
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due to the light scattering effect. Moreover, the infarct region contains largely 
fibrotic scars intermingled with surviving myocardial fibers and adhesions from 
the pericardium caused by the surgery. Therefore, the signal from the infarct 
region has lower signal-to-noise ratio than normal tissue. 
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4  Low Voltage Multiple Shock Therapy of VT 
in Canine Hearts with Healing Infarction 
  
4.1 Abstract: 
 
Introduction: ICD therapy is the most reliable treatment of ventricular 
arrhythmias in high-risk post-myocardial infarction (MI) patients. However, 
high-voltage shocks may induce local injury current and contribute to the 
progression of heart failure. Previously, we achieved a significant reduction in the 
cardioversion threshold (CVT) by applying five monophasic (MP) shocks within 
one ventricular tachycardia (VT) cycle length (CL) in a rabbit model of chronic 
infarct. In this study, we aimed to extend these findings to a more clinically 
relevant canine model of healing infarct and to optimize the number of the 
multiple pulses. 
 
Methods: The left anterior descending artery of mongrel dogs (n=20) was 
occluded for two hours then reperfused via a left lateral thoracotomy.  Four days 
later, median sternotomy was performed and the animal was placed on 
cardiopulmonary bypass.  An 8 French pace/sense/shock lead was placed in the 
right ventricular (RV) apex and a 15 cm2 epicardial patch was sewn to the 
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posterior left ventricle (LV).  Epicardial mapping was performed in X dogs using 
a custom-made multi-electrode sock.  VT was induced by programmed 
stimulation, and defibrillation thresholds (DFT) of therapies delivered from the 
RV lead to LV patch were determined using a voltage-regulated step-up protocol.  
1 MP shock was applied at 0, 20, 40, 60, 80% coupling interval of one VT CL to 
determine phase dependency of the DFT.  DFT of 3, 5, 7 MP shocks or 10 MP 
shocks  applied within one or two VT CLs, respectively, were compared to a single 
MP shock.  Efficacy of anti-tachycardia pacing (ATP) applied from the RV bipolar 
lead was also examined. 
 
Results: One dog died suddenly one day after MI, and in one dog we were only 
able to induce polymorphic VT.  Of the eighteen remaining dogs, sustained VT 
with averaged CL of 177 ± 40 ms was reproducibly induced in ten dogs (n=10).  
We identified a total of 26 different surface ECG morphologies of monomorphic 
VT in these ten hearts, yielding an average of 2.6 ± 0.8 distinct morphologies per 
heart.  The DFT of a single MP shock was phase-dependent, ranging from a 
minimum of 0.3 ± 0.2 J to a maximum of 5.9 ± 2.5 J (p = 0.008).  10MP shocks 
applied in 2 VT CLs achieved the lowest DFT (0.04 ± 0.02 J), compared to 3, 5 or 
7 MP shocks applied in 1 VT CL (0.13 ± 0.09, 0.08 ± 0.04, 0.09 ± 0.07, 
respectively, p < 0.001). 10MP shocks reduced maximum CVT by 99% compared 
to 1MP (0.08 ± 0.09 vs. 5.9 ± 2.5 J, p = 0.007). The success rate of ATP was 
12.1% overall. 
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Conclusions: Our results suggest that a major reduction in energy can be 
achieved by using multiple shocks rather than a single shock to terminate 
monomorphic VT. And for stable reentry VT, multiple shocks are much more 
efficient than ATP in destabilizing the reentrant circuit. 
 
4.2  Key Terms 
 
Ventricular tachycardia, low-voltage, cardioversion, canine, infarct   
4.3 Introduction 
 
Sudden cardiac death accounts for 300,000 to 400,000 death annually in the 
United States 81, most commonly due to ventricular tachyarrhythmias such as 
ventricular tachycardia (VT) and ventricular fibrillation (VF). More than 80% of 
victims of sudden cardiac death suffer from coronary artery disease (CAD) 82.  
Significantly, the most common sustained ventricular arrhythmia in patients with 
prior myocardial infarction is re-entrant monomorphic VT 4.  
 
Anti-arrhythmic drug (AAD) and implantable cardioverter-defibrillator (ICD) 
therapies remain the major tools for the prevention and termination of life-
threatening ventricular tachyarrhythmias.  Several randomized, prospective 
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clinical trials have demonstrated the superiority of ICD therapy to AAD therapy 
to decrease mortality in patients with increased risk of ventricular 
tachyarrhythmias 65, 67, 83, 84, including patients with coronary artery disease or 
prior myocardial infarction 66, 68, 85. However, high voltage ICD shocks have been 
shown to reduce the quality of life and are associated with an increased risk of 
mortality 86-88.  Anti-tachycardia pacing (ATP) can reduce the morbidity of ICD 
shocks, and was shown to terminate 78% to 94% of VT episodes with cycle 
lengths longer than 320 ms 77, 89, 90, however the efficacy decreased (41% -79%) 
and the probability of accelerating tachycardia increased (5-55%) when targeting 
VT with cycle length shorter than 300 ms 91, 92. Catheter ablation is another 
common treatment of sustained monomorphic VT. However, VT with multiple 
morphologies recurs in 19-50% of the patients. Besides, the procedure requires 
patients remain in sustained VT for a relatively long period of time, which might 
cause procedure mortality and many other major complications 93.  
In this study, we adopted a well-established canine model 94-96 of inducible 
monomorphic VT following myocardial infarction reentrant circuits are sustained 
by slow and anisotropic conduction that occur in the epicardial border zone 97, 98.  
 
Previously, we showed that the cardioversion thresholds (CVT) of single 
monophasic (MP) and single biphasic (BP) shocks varied significantly depending 
upon the phase of the VT cycle in which it was delivered, using a rabbit ex vivo 
chronic myocardial infarction model of VT 54, 99.  The optimal phase of shock 
delivery was determined empirically, not a priori.  Importantly, we overcame this 
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limitation by applying multiple monophasic (MP) shocks within one VT cycle 
length, which reduced the cardioversion threshold (CVT) significantly relative to 
single shocks 99.  Mechanistically, we demonstrated that this multiple low-energy 
shock therapy acts to keep a small area of excitable gap depolarized until the VT 
wavefront collides with it, as opposed to depolarizing a large area by a single 
high-energy shock. The goal of this study was to extend these findings to a more 
clinically relevant canine model of healing infarction and to optimize the number 
of shocks for the low-energy multiple-shock therapy. 
 
4.4 Methods 
 
4.4.1   Surgical Procedures 
 
Mongrel dogs (N=20) of either sex weighting 20-25 kg were induced with 
propofol (7.5 mg/kg intravenously), maintained on inhalation anesthetic (2-3% 
isoflurane in oxygen) while a lateral thoracotomy was performed.  The left 
anterior descending (LAD) coronary artery immediately distal to the first 
diagonal branch was occluded by ligation for 2 hours, followed by reperfusion to 
create an MI.  In cases where the LAD was continuous with the posterior 
descending artery, the LAD was also ligated at the apex.  Lidocaine (2 mg/kg 
bolus over 10 minutes) was given prior to LAD ligation and again prior to 
reperfusion to limit ventricular arrhythmias.  The surgical procedures have been 
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described previously 94. The right femoral artery was cannulated for continuous 
blood pressure monitoring and periodic measurements of pH and electrolytes.  
One animal died suddenly one day after infarction.  
 
In the remaining 19 dogs, defibrillation studies were performed 4 days after 
infarction. Each animal was re-induced and anesthetized similarly, and a right 
femoral arterial line was placed.  Median sternotomy was performed and the 
heart was exposed in a pericardial cradle.  After systemic heparinization (target 
activated clotting time > 300 sec), the animal was placed on cardiopulmonary 
bypass in order to maintain stable hemodynamics during sustained VT. 
 
4.4.2   Electrode Configuration 
 
As shown in Figure 4.1A, an 8 French lead with a single 5.5 cm distal shock coil 
and pace/sense bipole (St Jude Medical, St. Paul, MN) was implanted into the 
right ventricle (RV) for delivery of shock and pacing therapies.  A defibrillation 
patch (15 cm2) was placed over the epicardial surface of the posterior left 
ventricle (LV).  A bipolar button electrode was sewn to the anterior LV 
epicardium for ventricular sensing.  Continous surface electrograms were 
recorded during each experiment. 
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In 2 dogs, we mapped the VT circuit using a custom made 253-pole electrode 
sock that was sewn to the anterior LV.  The sock covered the infarct border zone 
as shown in Figure 4.1B. 253 unipolar ventricular electrograms (VEG) with 3-5 
mm interelectrode distance were then recorded in sinus rhythm and during VT. 
After the placement of electrodes, ventricular shock excitation thresholds (SET) 
were measured using a 10 ms monophasic square wave delivered from RV coil to 
LV patch and vice versa during the diastolic interval. 
? 
Figure  4.1.  Electrode  patch  and  epicardial  activation  map  during  pacing (CL=300ms).    Position  of  253‐pole  sock  electrode  used  to  map  the  reentrant  VT circuit seen in (A) RAO and (B) LAO views.  RV, right ventricle; LV, left ventricle. 
 
4.4.3   Induction of Ventricular Tachycardia 
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To promote sustained VT (lasting more than 30 seconds) in this model, we 
administered loading (2 mg/kg) and maintenance (0.05 mg/kg/min) infusions of 
flecainide acetate (Sigma-Aldrich, St. Louis, MO) intravenously. Ventricular 
effective refractory period (ERP) was measured before and after flecainide 
administration. Ventricular arrhythmia was induced by programmed stimulation 
delivered through the endocardial RV bipole via a stimulus isolator (A365R; 
World Precision Instruments, Sarasota, FL). 
 
VF was defined as a ventricular rate exceeding 500 bpm (cycle length shorter 
than 120 ms) with disorganized ECG morphology.  In all experiments, VF was 
terminated using an external defibrillator that delivered a single biphasic shock 
across the heart via hand-held paddles (Heartstart XL, Philips Electronics, 
Amsterdam, Netherlands).  After each successful external defibrillation, 
induction of VT was withheld for five to ten minutes to allow recovery of the 
myocardium. 
 
4.4.4   Defibrillation Waveforms 
 
All defibrillation therapies were delivered from the RV lead-LV patch vector.  A 
single monophasic shock (1MP, 10 ms) was applied at various phases (0%, 20%, 
40%, 60%, 80%) of one VT cycle length to determine the phase-specific DFT.  
The DFT of three, five or seven monophasic shocks applied within one VT cycle 
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length (3MP, 5MP and 7MP, respectively), or ten monophasic shocks delivered 
within two VT cycle lengths (10MP) were compared to that of a single MP shock 
(Figure 4.2).  DFT was defined as the shock amplitude, in volts, that terminated 
the VT.  The DFT for each therapy (1MP, 3MP, 5MP, 7MP, 10MP) was 
determined sequentially, and the cycle was then repeated until the experiment 
was terminated.  DFTs were determined using a voltage-regulated up-down 
protocol in which the amplitude of the shock voltage was increased in 20% 
increments beginning at twice the shock excitation threshold until cardioversion 
was achieved.  Once a DFT for a given therapy was determined, subsequent 
attempts were begun at 80% of the previous DFT.  1MP shocks were delivered 
from an external defibrillator (Ventritex, Sunnyvale, CA). All multiple-shock 
therapies were delivered by a custom built LabVIEW software program (National 
Instruments, Austin, TX) and amplified by a computer-controlled, regulated 
power supply (BOP 100-4M; Kepco, Flushing, NY).  The impedance was 
measured using a current probe (A622; Tektronix, Inc., Beaverton, OR). 
Antitachycardia pacing (ATP; eight pulses with an interval of 88% of VT cycle 
length) was applied in all animals through the RV endocardial bipolar pacing 
lead.  
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Figure 4.2. CVTs of all Shock waveforms were measured and compared. 1MP: one monophasic  shocks  that  applied  at  different  coupling  interval  of  the  VT  CL.  3MP, 5MP, 7MP: three, five, and seven monophasic shocks that applied within one VT CL. 10MP: ten monophasic shocks applied within two VT CL.  
4.4.5   Data Analysis 
 
Local activation times were defined as the time of the maximum negative 
derivative in each unipolar VEG. All VEGs were edited visually to verify accuracy 
of the computer-recognized activation times. Activation maps were constructed 
using the isochrones of the activation times for all VEGs. 
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The minimum and maximum CVTs of 1MP shock, the maximum CVTs of 1MP 
shock and that of 10MP shocks were compared using an unpaired Student’s t-
test.  CVTs for multiple shock thereapies (3MP, 5MP, 7MP, and 10MP) were 
compared using one-way analysis of variance (ANOVA).  Results are reported as 
mean ± standard deviation.  A p value of ≤ 0.05 was considered statistically 
significant. All statistical analyses were performed using SPSS (Version 19, IBM, 
Somers, NY).  
 
 
4.5 Results 
 
4.5.1   VT in Canine Hearts with 4-day Infarct  
Flecainide infusions allowed us to reproducibly induce sustained monomorphic 
ventricular tachycardia in ten of nineteeen dogs (52.6 %).  One dog did exhibited 
only sustained polymorphic VT.  The ventricular effective refractory period was 
significantly prolonged by administration of flecainide (155 ± 19 ms vs. 172 ± 18 
ms, p = 0.002).  VT cycle lengths ranged from 120 to 250 ms (mean CL 177 ± 40 
ms).  We identified a total of 26 different ECG morphologies of monomorphic VT 
in the remaining ten hearts (an average of 2.6 ± 0.8 VT morphologies per heart).   
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Activation maps were constructed during initiation of VT by programmed 
stimulation. While induced monomorphic VT had uniform cycle length and 
stable QRS morphology, in some cases, initial ventricular depolarizations after 
delivered extrastimuli exhibited variable cycle length and QRS morphology. An 
example is shown in Figure 4.3. Crowding of isochrones and conduction 
slowing is observed at the infarct region during RV endocardial pacing at a cycle 
length of 300 ms. We observed lines of conduction block after delivering 
premature stimuli with a coupling interval of S1/S2=300/165 ms and during 
sustained reentry, but not during pacing at 300 ms. This suggests that the 
epicardial border zone provided functional conduction block and acted as the 
substrate to sustain the reentrant circuit. 
 
 
Figure 4.3. Initiation of VT by a pacing train followed by a single premature stimulus. A: 
Ventricular electrogram (VEG) during induction of VT. B-D: Epicardial activation maps 
with isochrones drawn in 15 ms increments were constructed in the time window outlined 
by the white box during (A) RV endocardial pacing at a cycle length of S1=300 ms, (B) a 
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premature stimulus at a coupling interval of S2=165 ms and (C) beginning of reentrant 
VT. The directions of wave front propagation are shown with arrows. Lines of 
conduction block in the reentrant circuit are denoted with bold dashed lines in C and D. 
 
4.5.2   Anti-tachycardia Pacing (ATP) 
 
ATP terminated VT in only 12 of 99 trials, with a success rate of 12.1% in a total of 
eleven hearts. Two ATP trials (2%) converted VT to VF. 
 
4.5.3   Ventricular Shock Excitation Threshold 
 
Ventricular shock excitation thresholds (SET) were measured for both polarities 
during sinus rhythm.  The SET of RV anodal shock was significantly lower than 
that of RV cathodal shock (1.0 ± 0.7 V vs. 1.5 ± 0.9 V, p = 0.017).  
 
4.5.4   Cardioversion Thresholds of a Single Monophasic 
Shock 
 
Figure 4.4 is an example of a 1MP shock, applied at an optimal phase, 
terminating sustained monomorphic VT after one extra beat.  The shock, with a 
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DFT of 0.1 J, was applied when the re-entrant wave front slowly entered the 
isthmus of the figure-of-eight reentry circuit.  After shock application, the earliest 
epicardial breakthrough appeared at the RV base. The line of conduction block 
disappeared during the postshock beat which has a wider cycle length at 290 ms. 
After an isoelectric interval of 703 ms, sinus rhythm was restored.  This finding 
demonstrates that reentrant circuits in this canine model of healing MI are 
sustained by functional conduction block at the epicardial border zone.  
 
 
Figure 4.4. A single monophasic shock with an amplitude of 25 V, was delivered at an optimal phase of the VT cycle and terminated a sustained VT with cycle length of 209 ms. 
 
Figure 4.5 is an example of a 1MP shock applied at a suboptimal phase.  
Although this shock does terminate VT, it does so only after eight extra beats.  
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Termination by this shock also required much higher energy (DFT = 6.0 J). Two 
lines of conduction block are shown in Figure 4.5 B with black dashed lines. 
Eventually, the lines of conduction block disappeared during the post-shock extra 
beats, and the stable reentrant circuit was destroyed by the shock, restoring sinus 
rhythm. 
 
 
Figure 4.5. A single monophasic shock with an amplitude of 190 V was delivered at a sub‐optimal phase of the VT cycle terminated a sustained VT with a cycle length of 215 ms after eight post‐shock extra beats. Shock eliminated the lines of conduction block by creating secondary sources via VEP effect. 
 
Figure 4.6 shows a representative plot of shock application phases versus DFT 
of 1MP shock in one animal.  Here, the minimum CVT is 0.42 J at 40% of the VT 
CL, whereas the maximum DFT for this animal is 5.1 J at 0% of the VT cycle 
length. This phase dependency of DFT was seen in all five hearts in which phase 
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dependency of DFT was tested.  Overall, the minimum versus maximum DFT of 
1MP shock applied at various phases was 0.3 ± 0.2 J versus 5.9 ± 2.5 J, 
respectively (p = 0.008).  The optimal phase of shock application varied with 
different animals. 
 
 
 
Figure 4.6. CVT of a single shock is phase dependent.  A: Single monophasic shocks were delivered at 0%, 20%, 40%, 60% and 80% of the VT cycle length, indicated by the  solid  vertical  lines.    B:  CVT  as  a  function  of  phase  of  VT,  in  Joules.  EKG, electrocardiogram; VT, ventricular tachycardia; CL, cycle length; CVT, cardioversion threshold. 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4.5.5   Cardioversion Thresholds of Multiple Shock Therapies   
For multiple shock therapies, DFT, in Joules, was calculated by multiplying the 
energy of a single shock by the number of shocks that applied.  In Figure 6A, a 
1MP shock with energy of 1.1 J failed to terminate VT with a cycle length of 220 
ms. In the same animal, for a faster VT with cycle length of 170 ms, 3MP, 5MP, 
7MP, 10MP successfully restored sinus rhythm with DFTs of 0.24 J, 0.16 J, 0.2 J, 
and 0.06J, respectively.  Figure 4.7 shows representative examples of 
cardioversion by a single monophasic shock and by multiple shock therapies with 
different number of shocks.  
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Figure 4.7.  Representative  Examples  of  Single‐  and Multiple‐Shock Therapies.    A: An  80V  single  monophasic  shock  failed  to  terminate  VT.    The  cardioversion thresholds of (B) 3 monophasic shocks, (C) 5 monophasic shocks, (D) 7 monophasic shocks  delivered  within  one  VT  cycle  length  and  (E)  10  monophasic  shocks delivered within two VT cycle lengths are shown. 
 
The mean DFTs of multiple shock therapies are shown in Figure 4.8. 10MP 
shocks, applied in two VT cycle lengths, achieved the lowest DFT with respect to 
both shock amplitude and total energy (4.9 ± 1.2 V and 0.04 ± 0.02 J, 
respectively) compared to 3MP, 5MP, and 7MP shocks applied within one VT 
 79 
cycle length.  Amongst multiple shock therapies, 3MP applied in one VT cycle 
length had the highest DFT (15.3 ± 6.3 V and 0.13 ± 0.09 J).  Importantly, the 
maximum DFT of 1MP in each animal remained significantly higher than that of 
any of the multiple shock therapies. For example, maximum DFT of 1MP 
compared to that of 10MP shocks was 5.9 ± 2.5 J versus 0.08 ± 0.09 J, 
respectively (p = 0.007). Moreover, there was no significant difference between 
the maximum and minimum CVT measured in every animal for each multiple 
shock therapy.   
 
 
 
Figure  4.8.  Cardioversion  Thresholds  of  Multiple  Shock  Therapies.    The Cardioversion Thresholds  in  (A) Voltage and  (B) Energy are  shown  for 3, 5 and 7 monophasic  shocks  (3MP,  5MP  and  7MP,  respectively)  delivered  within  one  VT cycle  length  and  10  monophasic  shocks  (10MP)  delivered  within  two  VT  cycle lengths. 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4.6 Discussion 
 
In accordance with our previous studies on a single monophasic and a single 
biphasic shock in an ex vivo chronic myocardial infarction rabbit heart model of 
VT, the DFT of 1MP shock is highly phase-dependent for terminating 
monomorphic VT in the in vivo healing infarction canine model of VT.  
Unfortunately, the optimal phase of the VT cycle in which 1 MP shock can 
terminate VT varies from animal to animal.  Significantly, multiple shock 
therapies applied during one or two VT cycle lengths overcomes this phase-
dependency and terminates monomorphic sustained VT with significantly more 
efficacy than a single shock.  Amongst the multiple shock therapies tested, 3MP 
shocks delivered within one VT cycle length had the highest DFT, whereas 10MP 
shocks delivered within two VT cycle lengths had the lowest DFT (0.13 ± 0.09 J 
versus 0.04 ± 0.02 J, respectively, p < 0.001).  Finally, ATP therapy, applied from 
right ventricular endocardial bipole, terminated VT only 12.1 % of the time in this 
model. 
 
We induced sustained monomorphic VT, in ten of nineteen (52.6%) canine hearts 
with healing myocardial infarction with the administration of flecainide.  Several 
groups have shown that the inducibility of sustained VT without flecainide in this 
model is relatively low, ranging from 23%~47% 96, 100, 101.   Similar to our 
observations, these prior studies demonstrated that the mechanism of VT 
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induced by programmed stimulation in this canine model is due to functional 
block at a region of the epicardial infarct border zone, thereby creating a 
reentrant circuit.  Although the surviving border zone has some normal 
histological features, there is also varying degrees of disruption of Connexin43 
that occurs in a time-dependent manner, similar to that discovered in healed 
human infarcts.  Therefore, the inducibility of sustained VT depends on the 
functional properties of the tissue, specifically, the infarct border zone. Peters et 
al. showed that a stable reentrant circuit leading to sustained, monomorphic VT 
appears to occur only if the lateralization of connexin43 extends throughout the 
full thickness of a region in the infarction border zone, which defines the 
locations of the lines of conduction block 60.  Coromilas et al. showed that 
flecainide converted inducible unsustained monomorphic and polymorphic VT to 
sustained monomorphic VT by lengthening the line of block and slowing 
conduction in both the longitudinal and transverse direction relative to the 
myocardial fiber orientation, whereas not causing complete conduction block in 
central common pathway 79. 
 
ATP has conventionally been targeted to only slow, presumably hemodynamically 
tolerated VTs.  Prior studies have demonstrated that ATP terminates 78% to 94% 
of monomorphic VT with cycle length longer than 300 ms, albeit with a 2% to 4% 
risk of accelerating VT to VF 102-104. Wathen et al. tested the efficacy of ATP for 
“fast” VT, in which the cycle length ranged from 240 to 320 ms, and found that 
ATP terminated 84% of VT episodes with median cycle length 280 to 320 ms 
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versus 69% of episodes with median cycle length 240 to 280 ms 91.  Other clinical 
trials tested ATP for fast VT in ICDs and found 47% to 79% success with a risk of 
acceleration to VT of 3% to 10% 77, 90, 92.  In this study, however, ATP applied from 
right ventricular endocardial bipolar pacing lead terminated induced 
monomorphic VT only 12% of the time.  This low success rate is likely due to the 
relatively fast VT induced in this model (mean cycle length 177 ms).  The 
relatively low success rate of ATP (41% to 68%) for VT induced in the 
electrophysiology laboratory has been shown by other studies 105-108.  The efficacy 
of ATP may also depend on the nature and the mechanism of VT, for example, 
functional or anatomical VT, conduction velocity of the wave front, cycle length of 
VT, and the methods used to induce VT. The location of the pacing electrode 
relative to the location of scar tissue might affect the success rate of ATP. 
 
We showed that the efficacy of a single monophasic shock was phase-dependent 
in the canine model of 4-day infarction, which indicates that the DFT could be 
significantly decreased if the shock is applied at the optimal phase. This result is 
consistent with our previous findings about the defibrillation efficacy of a single 
monophasic and biphasic shocks in ex vivo rabbit hearts with chronic myocardial 
infarction 54, 109.  Specifically, the average maximum DFT of a single shock was 20 
times higher than the average minimum DFT in this canine model.  The optimal 
phase, defined as the delivery phase with lowest DFT, varied between animals 
and could not be predicted a priori.  However, multiple shock therapies enables 
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similarly low DFT as a single shock without requiring knowledge of the optimal 
phase.  
 
Previously we studied the mechanism of defibrillation using five monophasic 
shocks applied within one VT cycle length in ex vivo rabbit hearts with chronic 
myocardial infarction 109.  We found that multiple shocks unpinned the reentrant 
circuit by maintaining a shock-induced depolarization effect, which increased the 
duration of refractory tissue until the reentrant wave front collided with the 
refractory tissue and was extinguished. In the same model, we also showed that a 
single monophasic shock has equally efficacy as a single biphasic shock, while 
multiple monophasic shocks have significantly higher efficacy than multiple 
biphasic shocks.  This phenomenon occurs because the second (inverted) phase 
of a biphasic shock reverses the virtual electrode polarization effect of the first 
phase and thus prevents prolongation of refractory tissue. In this study, we varied 
the number of shocks for the multiple shock therapy and extended it to a more 
clinically relevant in vivo model.  We found that 10MP shocks applied within two 
VT CL has the lowest DFT compared to 3MP, 5MP, and 7MP shocks applied 
within one VT CL.  The DFT of 10MP shocks was only five times the ventricular 
shock excitation threshold and only one hundredth of that of 1MP shock. 
Importantly, in this model, the voltage and total energy required for defibrillation 
using multiple shock therapy is comparable to that of ATP, yet with significantly 
higher efficacy.  Though multiple shock therapy may require design changes prior 
to incorporation into implantable cardioverter defibrillators, such therapies could 
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be delivered in far less time than a full output ICD shock, which requires the 
relatively slow process of fully charging the discharge capacitor.  Moreover, 
reducing the number of full output ICD shocks would reduce morbidity and likely 
prolong battery life in patients with repeated episodes of monomorphic VT who 
fail ATP.   
 
 
4.7  Conclusions 
 
In the present study, we found that the efficacy of a single monophasic shock in 
cardioversion of VT in canine hearts with healing myocardial infarction has a 
phase-dependent property. We also showed that multiple shock therapies were 
significantly more efficacious for cardioversion of VT than a single monophasic 
shock since they don’t display the phase-dependent manner. Importantly, we 
showed that ten monophasic shocks applied within two VT cycle lengths achieved 
the lowest CVT (4.9 ± 1.2 V; 0.04 ± 0.02 J), which is comparable to the energy of 
ATP therapy, which is shown to be ineffective in this model. Based on this study, 
we conclude that multiple shock therapy may become the new paradigm of low-
energy cardioversion of VT. 
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5 Low Energy Multi-stage Atrial Defibrillation 
Therapy 
 
 
5.1 Abstract 
 
Background: Implantable device therapy of atrial fibrillation (AF) is limited by 
pain from high-energy shocks.  We developed a low-energy multi-stage 
defibrillation therapy and tested it in a canine model of AF.  
 
Methods and Results: AF was induced during vagus nerve stimulation.  Our novel 
defibrillation therapy consisted of three stages: ST1 (1-4 low energy biphasic 
shocks), ST2 (6-10 ultra-low energy monophasic shocks), and ST3 (anti-
tachycardia pacing).  Firstly, ST1 testing compared single or multiple monophasic 
(MP) and biphasic (BP) shocks. Secondly, several multi-stage therapies were 
tested: ST1 versus ST1+ST3 versus ST1+ST2+ST3. Thirdly, three shock vectors 
were compared: superior vena cava to distal coronary sinus (SVC>CSd), proximal 
coronary sinus to left atrial appendage (CSp>LAA) and right atrial appendage to 
LAA (RAA>LAA). The atrial defibrillation threshold (DFT) of 1BP shock was less 
than 1MP shock (0.55 ± 0.1 versus 1.38 ± 0.31 J; p =0.004).  2-3 BP shocks 
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terminated AF with lower peak voltage than 1BP or 1MP shock and with lower 
atrial DFT than 4 BP shocks.  Compared to ST1 therapy alone, ST1+ST3 lowered 
the atrial DFT moderately (0.51 ± 0.46 versus 0.95 ± 0.32 J; p = 0.006) while a 
three-stage therapy, ST1+ST2+ST3, dramatically lowered the atrial DFT (0.19 ± 
0.12 J versus 0.95 ± 0.32 J for ST1 alone, p<0.001).  Finally, the three-stage 
therapy ST1+ST2+ST3 was equally effective for all studied vectors. 
 
Conclusions: Three-stage therapy significantly reduces the AF defibrillation 
threshold and opens the door to low energy atrial defibrillation at or below the 
pain threshold.  
 
 
5.2 Key Words  
 
Atrial fibrillation; defibrillation; cardioversion; vagal stimulation 
 
 
 
5.3 Introduction 
 
Atrial fibrillation (AF) is the most common tachyarrhythmia worldwide. The 
number of Americans afflicted by AF will increase to over 12 million by 2050,110 
placing a significant additional burden on the healthcare system. Moreover, 
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patients with AF suffer serious consequences including increased rates of 
thromboembolic stroke, congestive heart failure, cognitive dysfunction, and 
mortality.111-113  
 
Catheter ablation has become increasingly common for the treatment for AF but 
its success rate varies widely and it is beset by a significant rate of major and 
minor complications.  While success rates vary depending upon operator and 
patient selection, arrhythmia-free survival rates after a single catheter ablation 
procedure are less than 29% at 5 years.114 Complication rates will likely improve 
over time, yet risks such as stroke, pulmonary vein stenosis, phrenic nerve injury, 
and the rare but often fatal atrioesophageal fistula have made this a less than 
ideal treatment modality.115-118   
 
For symptomatic patients, cardioversion of AF to sinus rhythm using high-
voltage external shocks, with or without antiarrhythmic drugs remains a 
mainstay of therapy.  External cardioversion is painful and can lead to brady- and 
tachy- arrhythmias, necessitating anesthesia and careful peri-procedural patient 
monitoring. Hospitalization, anesthesia, personnel and ancillary procedures costs 
associated with AF is estimated to cost Medicare more than $15.7 billion 
annually.119  
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These considerations have prompted efforts to design an implantable device that 
converts AF to sinus rhythm safely.  Such a system would enable rapid 
cardioversion soon after the onset of AF, ameliorating symptoms and 
importantly, reducing the likelihood of atrial remodeling.120 Moreover, since 
internal atrial cardioversion requires significantly less energy than external 
cardioversion,121 it may be possible to deliver this therapy below the pain 
threshold, generally considered to be between 0.1-1 J.12,13  Several internal atrial 
cardioverters have been developed in the past122-124 but received limited 
acceptance primarily due to the discomfort associated with shocks.125-130 
 
Experimental and clinical studies have demonstrated that vagus nerve 
stimulation promotes sustained AF by decreasing the atrial effective refractory 
period (AERP) and AERP rate adaption in an anatomically heterogeneous 
manner, thus creating the substrate for maintenance of sustained AF.131, 132 This 
acute model readily produces sustained AF and has been used extensively to 
study mechanisms of and therapies for atrial fibrillation.133 The AF generated by 
this model was shown to be of significantly longer duration and higher dominant 
frequency compared to that induced by chronic rapid pacing, making it a 
reasonable model to study the electrotherapy of AF.134   
 
Previously, we compared multiple monophasic (MP) shocks to a single shock for 
defibrillation of atrial fibrillation and flutter in an ex vivo rabbit model135  and  in 
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a rabbit chronic infarction model of ventricular tachycardia.109 In both models, 
multiple monophasic shocks significantly lowered the defibrillation threshold.  
The goal of this study was to develop a low-energy therapy for defibrillation of AF 
in vivo.     
 
5.4 Methods 
 
5.4.1   Surgical Procedures 
 
Mongrel dogs (n=16) weighing 20-25 kg were intubated and anesthetized with 
propofol (7.5 mg/kg intravenously) and 2-3% inhaled isoflurane in oxygen 
(Model 2000; Hallowell EMC, Pittsfield, MA).  The right femoral artery was 
cannulated for continuous blood pressure monitoring and periodic 
measurements of arterial blood gas and electrolytes.  After median sternotomy, 
the pericardium was opened to expose the heart.  Bilateral carotid cut downs 
were performed to isolate the Vagus nerves.  Cuff electrodes (A0004-6, 
Evergreen Medical Technologies, LLC, St. Paul, MN) were placed around each 
nerve for subsequent stimulation.  
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5.4.2   Electrode Placement 
 
Bipolar electrodes were sutured to the right atrium for pacing, and left atrium 
and ventricular apex for sensing. Atrial and ventricular epicardial electrograms 
(EG) and surface electrocardiogram (ECG) were recorded continuously. 
 
Custom defibrillation disc electrodes 0.5 or 1 inch in diameter were sutured to the 
right and left atrial appendages (RAA and LAA, respectively) and superior vena 
cava (SVC).   A custom 4 French lead with two shock coils, each 1 inch in length, 
was placed into the coronary sinus (CS; Evergreen Medical Technologies, LLC, St. 
Paul, MN); the proximal and distal coils are referred to as CSp and CSd, 
respectively. A schematic of the defibrillation electrodes is shown in Figure 5.1.   
  
After the placement of electrodes, atrial and ventricular shock excitation 
thresholds (SET) were measured for each defibrillation electrode pair tested 
using a 10 ms square monophasic shock applied during the diastolic interval.  
 
5.4.3   Atrial Fibrillation Induction and Definitions  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Bilateral vagus nerve stimulation was performed with 10-20 V pulses of 1 ms 
duration starting at 4 Hz via a stimulator (SD9; Grass, West Warwick, RI). Atrial 
effective refractory period (AERP) was measured before and after vagal 
stimulation.  After 30 seconds of stimulation, AF was induced via right atrial 
burst pacing at 10-20 Hz at four times the atrial capture threshold via a stimulus 
isolator (A365R; World Precision Instrument, Sarasota, FL).  AF was defined as a 
rapid, irregular atrial rhythm with varying atrial electrogram morphology. 
Frequency of vagal stimulation was increased in 1 Hz steps until AF lasted 10 
minutes or longer. If atrial flutter (AFl) was induced, anti-tachycardia pacing 
(88% of cycle length) or multiple-shock therapy was applied to restore sinus 
rhythm.  Vagus nerve stimulation was then resumed with a higher frequency.  
After every successful termination of AF or AFl, stimulation was withheld for five 
minutes to allow recovery of the nerve. 
 
 
Figure 5.1. Anatomic  Positions  of Defibrillation Electrodes.  Schematic  of  a  canine heart  with  locations  of  electrodes  from  which  defibrillation  therapies  were 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delivered  depicted.  A:  right  anterior  oblique  (RAO)  view  showing  superior  vena cava and right atrial appendage disc electrodes. B: left anterior oblique (LAO) view showing left atrial appendage disc electrode.  C: posteroanterior (PA) view showing distal and proximal coronary sinus coils.  SVC, superior vena cava; RA, right atrium; PT, pulmonary trunk; RV, right ventricle; LV,  left ventricle; CSp, proximal coronary sinus; CSd, distal coronary sinus.  
 
5.4.4   Defibrillation Vectors and Waveforms 
 
After inducing AF, we determined the peak voltages and atrial DFTs of the 
waveforms depicted in Figure 5.2A.  Single monophasic (1MP, 10 ms) or 
biphasic (1BP, 6/4 ms) shocks, and multiple monophasic (2MP) or biphasic 
shocks (2BP, 3BP, 4BP) were delivered across a single vector oriented from RAA 
to LAA.  In all cases, the initial shock was delivered on the R-wave and triggered 
via the ventricular electrogram or surface ECG. The multiple shocks were applied 
within 100 ms, which was shorter than the ventricular ERP, to avoid induction of 
ventricular fibrillation.   
 
Next, we tested multiple stage defibrillation therapies (Figure 5.2B). Stage 1 
therapy (ST1) consisted of two BP shocks (10-100V) applied within a single cycle 
length (CL) of AF. The cycle length of AF was determined based on the dominant 
frequency of AF induced.  Stage 2 therapy (ST2) consisted of 6-10 lower energy 
MP shocks applied across the same vector as in ST1.  All ST2 shocks were 
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delivered at or above the atrial shock excitation threshold (SET) but below the 
ventricular SET, thus capturing atrial but not ventricular tissue.  ST2 shocks were 
delivered at a rate 70-100% that of the AF CL.  Stage 3 therapy (ST3) consisted of 
6-10 bipolar right atrial pacing stimuli delivered at 70-100% of the AF CL.  The 
following combinations of stages were tested: (i) ST1, (ii) ST1+ST3, and (iii) 
ST1+ST2+ST3.  The delay between each stage was 100-400 ms. 
 
 
Figure  5.2.  Waveforms  and  Stages  of  Low  Energy  Defibrillation  Therapy.  A: Individual waveforms tested in Stage 1 (ST1) of the three‐stage therapy. B: ST1+ST3 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therapy. ST1 consists of 2 biphasic shocks delivered within 30‐50% of the AF cycle length.   ST3 consists of 8 bipolar atrial pacing stimuli delivered at 70‐100% of the AF  cycle  length. C:  ST1+ST2+ST3  therapy.  ST1  consists  of  2  biphasic  shocks.  ST2 consists of 8  lower voltage monophasic shocks, and ST3 consists of 8 atrial pacing stimuli.   Each pulse in ST2 and ST3 is delivered at 70‐100% of the AF cycle length.  In  both  B  and  C,  a  delay  of  100‐400  ms  separates  each  stage  of  therapy.  MP, monophasic  shock; BP, biphasic  shock; AF,  atrial  fibrillation; CL,  cycle  length.  ST1, stage 1; ST2, stage 2; ST3, stage 3. 
 
Finally, we determined the atrial DFTs of three defibrillation vectors: SVC to CSd, 
LAA to CSp, and RAA to LAA.  For each vector, three combinations of therapy 
(described above) were tested.  All therapies were delivered by a custom built 
LabVIEW software program (National Instruments, Austin, TX) and amplified by 
a computer-controlled, regulated power supply (BOP 100-4M; Kepco, Flushing, 
NY). The impedance of each defibrillation vector was measured using a current 
probe (A622; Tektronix, Inc., Beaverton, OR). 
 
5.4.5   Statistical Analysis  
The far-field excitation threshold, atrial refractoriness, and frequencies of vagus 
nerve stimulation for different atrial tachyarrhythmias were compared using an 
unpaired Student’s t-test.  Atrial DFTs for each waveform/defibrillation vector 
combination were compared using one-way analysis of variance (ANOVA).  
Results are reported as mean ± standard deviation.  A p value of ≤ 0.05 was 
 95 
considered significant. All statistical analyses were performed using SPSS 
(Version 19, IBM, Somers, NY).  
 
 
5.5 Results 
 
5.5.1   Atrial Fibrillation Model  
Sustained AF was induced in 12 out of 16 animals.  Characteristics of the AF 
generated are shown in Figure 5.3.  AERP decreased significantly during vagal 
stimulation (79.6 ± 8.7 ms vs. 117.1 ± 14.7 without stimulation, p < 0.001).  In 
general, durations of AF increased with the frequency of vagus nerve stimulation, 
and the stimulation frequency that sustained AF was significantly shorter than 
that which sustained atrial flutter (AFL; 6.7 ± 2.1 Hz vs. 12.0 ± 4.4 Hz, p = 0.03).  
As expected, average dominant frequency of sustained AF was significantly 
higher than that of AFl (7.7 ± 0.4 Hz vs. 10.4 ± 1.4 Hz, p = 0.004).  
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Figure 5.3. Characteristics of Vagus Nerve Stimulation and Induced Arrhythmias. A: Mean  frequency  of  vagal  nerve  stimulation  (VNS)  during  induction  of  atrial fibrillation (AF) and atrial flutter (AFl).  B: Mean dominant frequency of AF and AFl induced by burst pacing during VNS. C: Effect of VNS on atrial effective  refractory period (ERP).  All values are reported as mean ± standard deviation. 
 
5.5.2   Shock Excitation Threshold 
 
Atrial and ventricular SETs were measured for each defibrillation vector and for 
both polarities during sinus rhythm before induction of AF.  A representative 
example of SET measurement is shown in Figure 5.4.  In this case, a 0.5 V, 10 
ms shock failed to capture atrial or ventricular tissue (Figure 5.4A), while a 1 V 
shock captured the atria but not the ventricles (Figure 5.4B).  Increasing the 
shock amplitude to 6.5 V captured both atria and ventricles (Figure 5.4C).  
 
Changing shock polarity did not significantly alter atrial or ventricular SET 
(Figure 5.5A). The atrial SET was significantly less than the ventricular SET for 
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each vector tested (Figure 5.5B). This finding enabled the application of ST2 
shocks above the atrial SET and below the ventricular SET delivered outside the 
ventricular refractory window without inducing ventricular tachycardia or 
fibrillation (VT or VF, respectively). 
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Figure 5.4. Determination of Atrial and Ventricular Shock Excitation Thresholds. An example of the surface electrocardiogram (EKG), atrial (AEG) and ventricular (VEG) electrograms,  respectively,  recorded  during  the  measurement  of  atrial  and ventricular shock excitation thresholds (SET)  for shock vector RAA>LAA is shown.  
A: 0.5 V shock captured neither atrial nor ventricular tissue.  B: 1 V shock captured 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atrial but not ventricular tissue. C: 6.5 V shock captured atrial and ventricular tissue. A, atrium; V, ventricle. 
 
 
Figure  5.5.  Shock  Excitation  Thresholds  are  Independent  of  Polarity  and 
Electrode Position. Mean atrial and ventricular shock excitation threshold (SET) is shown  for  different  electrode  sizes  and  individual  vectors  tested.    A:  Reversing polarity of the shock vector did not reduce SET significantly.  Atrial (black bars) and ventricular (white bars) SETs from two vectors using 1.0 in diameter disc electrodes placed  on  the  left  and  right  atrial  appendages  (LAA  and  RAA,  respectively)  is depicted.    For  each  vector,  notation  is  anode >  cathode.   B: Atrial  and  ventricular SETs for the three vectors tested using 0.5 in diameter disc electrodes and a 4F CS lead  with  two  1  in  coils.    C:  Impedances  for  each  vector  tested.    Note  that  the RAA>LAA  impedance using 0.5  inch  electrodes  (0.5”) was  larger  than  for 1.0  inch electrodes (1”), resulting in increased ventricular SETs for the 0.5 inch electrodes.  
 
5.5.3   Testing MP versus BP and single versus multiple 
shocks  
Atrial DFTs for ST1 shock waveforms are summarized in Figure 5.6, with peak 
shock voltage in the upper panel and total energy in the lower panel. Total energy 
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was calculated as the sum of the energies of individual shocks.  In all cases, AFl 
was easily terminated by a single BP shock at 0.0003 ± 0.0001 J or anti-
tachycardia pacing (ATP) with successful rate of 100% for each therapy.  For 
termination of AF, the atrial DFT of 1BP shock was significantly lower than that 
of 1MP shock (0.55 ± 0.1 J vs. 1.38 ± 0.31 J, p =0.004). Similarly, the atrial DFT 
of 2BP shocks was significantly lower than that of 2MP shocks (0.72 ± 0.19 J vs. 
1.92 ± 0.56 J, p < 0.001). Interestingly, the atrial DFT of 4BP shocks was 
significantly higher than that of 2BP (1.50 ± 0.50 vs. 0.72 ± 0.02 J, p = 0.018), 
since the voltages required to terminate AF were similar for 2, 3 and 4 BP shocks.  
Additionally, though the efficacy of 1 BP shock was lower compared 2 BP shocks, 
the peak voltage was significantly higher.  Therefore, we deemed 2 BP shocks to 
be the optimal waveform and chose it as the first stage (ST1) of subsequent 
multiple-stage therapy.  
 
Figure 5.6. Peak Voltage  and Total Energy of  Stage 1  therapies. For  each  therapy tested  in  Stage  1  (ST1),  peak  voltage  (A)  and  total  energy  (B)  is  shown.    MP, monophasic  shock;  BP,  biphasic  shock;  the  number  preceding  the  shock  type describes the number of shocks delivered, e.g., 1MP denotes a single MP shock while 4BP denotes four sequential BP shocks. 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5.5.4   Development of a low energy multiple stage 
defibrillation therapy 
 
2BP shocks (ST1) proved an optimal compromise with respect to peak voltage 
and total energy for cardioversion of AF in this model.  Next, we asked whether 
additional stages, such as sub-ventricular excitation shocks (ST2) and ATP (ST3) 
further lowered the atrial DFT. Figure 5.7 shows a representative example of AF 
termination by one-stage, two-stage, and three-stage therapies and the 
corresponding atrial DFTs. The summarized results are shown in Figure 5.8.  
2BP shocks followed by ATP (S1+S3) reduced the atrial DFT to 0.51 ± 0.46 J 
compared to 0.95 ± 0.32 J for ST1 alone (shock vector RAA>LAA, p=0.006).  
Significantly, atrial DFT was dramatically reduced further by the combination of 
2 BP shocks followed by sub-ventricular SET shocks and then ATP 
(ST1+ST2+ST3).  This “three-stage therapy” reduced the atrial DFT by nearly 
four-fold to 0.19 ± 0.12 J (vs 0.95 ± 0.32J for ST1 alone, p<0.001).  The three-
stage therapy was then tested across multiple vectors. 
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Figure 5.7. Representative Atrial Electrograms of AF Terminations. For each panel, peak voltage in Stage 1 (ST1) and total energy is denoted above the corresponding atrial electrogram.  The time that each individual therapy was delivered is indicated with an arrow.   A: ST1 therapy of  two 100 V biphasic shocks (total energy 1.14  J) terminated AF.  B: Stage 1 plus Stage 3 (ST1+ST3) lowered the peak voltage of ST1 to 70 V and the atrial defibrillation threshold (DFT) to 0.56 J.  C: Three‐stage therapy (ST1+ST2+ST3) dramatically reduced the total energy to 0.05 J and the peak voltage of ST1 to 20 V. 
 
5.5.5   The relationship of shock vector to atrial DFT 
 
We applied the three-stage therapy across three vectors: LAA-RAA, RAA to CSd, 
and CSp-LAA. Surprisingly, we detected no significant difference in atrial DFT 
(Figure 5.8D).  
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Figure 5.8. Atrial DFTs  for each Shock Vector  tested. Atrial DFTs of ST1, ST1+ST3 and ST1+ST2+ST3 are shown for each vector tested in total energy.  A: Shock vector SVC>CSd.   B: Shock vector CSp>LAA.   C: Shock vector RAA>LAA.   D: Atrial DFT of Three‐Stage  therapy  (ST1+ST2+ST3)  did  not  significantly  differ  with  respect  to shock  vector  tested.    SVC,  superior  vena  cava;  CSd,  distal  coronary  sinus;  CSp, proximal coronary sinus; LAA, left atrial appendage; RAA, right atrial appendage. 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5.5.6   Safety considerations 
 
Two out of a total of 3444 AF termination attempts induced VF. One episode was 
caused by improperly triggered ST1 application (not delivered on the R-wave) 
due to unexpected noise in the ventricular electrogram.  Adding an R-wave 
recognition algorithm in the trigger function and using the surface ECG as the 
trigger input when the signal-to-noise ratio of ventricular electrogram was poor 
overcame this problem.  The second VF episode was induced by ST2 shocks when 
the applied shock amplitude was very close to the ventricular SET. This problem 
was avoided in subsequent trials by strictly limiting the amplitude of ST2 shocks 
to below 50% of the ventricular SET.   
 
5.6 Discussion 
 
The main findings of the present study are as follows:  
1. Single and multiple biphasic shocks in ST1 were significantly more 
efficacious at terminating AF than the same number of monophasic 
shocks,  
2. Increasing the number of biphasic shocks in ST1 above two did not 
decrease the atrial DFT in this model,  
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3. A three-stage therapy ST1+ST2+ST3 significantly reduced the atrial DFT 
compared to one-stage (ST1) and two-stage (ST1+ST3) therapies,  
4. Three tested defibrillation vectors (RAA-LAA, RAA-CSd, LAA-CSp) were 
equally efficacious for all tested combinations of stages of therapy (ST1, 
ST1+ST3 and ST1+ST2+ST3). 
 
A prevailing theory is that AF is induced and maintained by a single or a small 
number of stable, self-sustained mother rotors giving rise to exceedingly high 
frequency excitation, with resultant fibrillatory conduction in the atria.136 Rotors 
are organized around phase singularities which tend to anchor to anatomical or 
functional syncytial heterogeneities.52 Attempts to optimize electrotherapy of 
fibrillation should be based on directly targeting the phase singularities.136-138 We 
have, however, demonstrated that electrotherapy may fail to defibrillate despite 
successful termination of phase singularities that maintain the ongoing 
arrhythmia.  This occurs because defibrillation simultaneously terminates 
existing phase singularities while inducing new phase singularities via the virtual 
electrode induced phase singularity mechanism.139 Biphasic shocks with 
appropriate energy ratios between the first and second phases can create 
homogeneous post-shock transmembrane polarization and phase distribution, 
which reduces the probability of inducing new phase singularities. 44 Therefore, 
an optimized biphasic shock therapy was proven safe and reliable in treating 
AF.122  
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The atrial DFT of a conventional single biphasic shock remains above the human 
pain threshold.125-130 This fact greatly limits implantable device therapy for 
cardioversion of AF.  High voltage shocks also cause electroporation140 and 
impair efferent sympathetic neural function.141 The three-stage AF therapy 
developed and tested in the present study is below the thresholds of 
electroporation and nerve damage.140-142 Most importantly, the energies and 
voltages necessary to cardiovert AF using multi-stage therapy are well likely 
below the human pain threshold,12 making realistic the possibility of an 
implantable device for defibrillation of AF.  
 
We previously found that multiple monophasic shocks achieve lower 
defibrillation thresholds than biphasic shocks in an in vitro model of VT in 
chronically infarcted rabbit hearts.109 In contrast, this study shows that multiple 
biphasic shocks are superior for the defibrillation of AF, a finding that is 
consistent with the studies of traditional high energy, single shock 
defibrillation.31, 32 The apparent discrepancy in findings between these studies 
may be explained by different mechanisms of low-energy defibrillation in these 
different tachyarrhythmias. VT, in the rabbit model, was maintained by a single 
rotor with phase singularity attached to a chronic infarction scar.  Successful 
multiple-shock low-voltage defibrillation was achieved by maintaining a small 
region refractory in the reentry circuit via the VEP effect induced by monophasic 
shocks until the wave front crashed into this refractory region and terminated.  
Accordingly, the second phase of biphasic shocks reverses the VEP effect of the 
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first phase and is therefore disadvantageous.109 Hence, biphasic shocks have 
higher DFTs compared to monophasic shocks for termination of VT.  In contrast, 
AF is sustained by multiple rotors with different frequencies, phases, and 
anatomical locations. Therefore, extinguishing all existing rotors is fundamental 
to the defibrillation of AF.135 This is better achieved by biphasic shocks, which 
create a more homogenous VEP pattern than monophasic shocks, and provides a 
mechanistic explanation of our findings in the present study.   
 
Another important difference between the defibrillation of VT versus AF is the 
optimal number of shocks.  In a canine infarct model of VT, we found that three 
monophasic shocks had the highest DFT, while ten monophasic shocks applied 
within two VT cycles had the lowest DFT compared to one, three, five, and seven 
monophasic shocks applied within one VT cycle.99  In the present study, we 
demonstrated that applying more than two biphasic shocks in ST1 did not lower 
the DFT. This difference suggests fundamental differences in the mechanisms of 
defibrillation of a relatively slow and more organized VT wave front versus a 
faster and more disorganized collection of wave fronts seen in AF; a longer train 
of shocks in a short interval could lead to defibrillation failure not by failing to 
terminate the existing disorganized wave fronts per se, but rather, by inducing 
new wave fronts.74  Moreover, from a neurological point of view, a smaller 
number of shocks is advantageous in developing a painless AF cardioversion 
strategy, as perceived pain increases with increasing number of shocks.143  
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Our three-stage therapy significantly lowers the energy for cardioversion of AF by 
application of three different stages of therapy, which we mechanistically relate to 
the: (1) unpinning of wave fronts that maintain AF, (2) prevent re-repinning of 
wave fronts to tissue heterogeneities such as scar, and (3) annihilation of 
remaining wave fronts.  The unpinning stage uses multiple pulses aiming to 
unpin the reentry from the stabilizing resistive heterogeneity. The applied electric 
field creates stronger virtual electrode polarization at tissue heterogeneities, 
which causes excitation and then unpinning of the reentry.51, 52 However, this 
stage leaves behind a number of unpinned phase singularities which could then 
re-pin to heterogeneities and perpetuate AF. Thus, the anti-repinning stage likely 
prevents the meandering singularities from anchoring back to the tissue 
heterogeneities by applying an entrainment shock train.144 After the first two 
stages, the last stage adopts anti-tachycardia pacing to drive the remaining 
reentry circuits to the boundaries of the atria, i.e., tricuspid or mitral annulus, 
vena cavae, or pulmonary veins, thereby annihilating the arrhythmia to restore 
sinus rhythm109, 135, 145. 
 
AF is rarely fatal, yet atrial defibrillation stimuli could lead to VF, as was found 
earlier146 and in our study.  Accordingly, the safety of any atrial defibrillation 
therapy must be considered the highest priority. Our study revealed several 
techniques to improve safety. Synchronization of the first stage shocks to the R-
wave to deliver it within the ventricular ERP is critical to avoiding potentially 
lethal post-shock ventricular arrhythmias. Similarly, the shock amplitude of the 
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second stage has to be significantly below the ventricular shock excitation 
threshold.  We found that delivering the second stage below 50% of the 
ventricular SET provided an adequate safety margin and prevented unintended 
ventricular excitation. 
 
Prior studies of atrial defibrillation delivered shocks from a CS coil to an RA coil 
positioned along the lateral wall in order to minimize damage to the sinoatrial 
and atrioventricular nodes.147 Our studies indicated that a defibrillation vector 
involving the coronary sinus may enhance the probability of inducing VF due to 
the relative ease of exciting ventricular tissue from the canine CS. In contrast, the 
human coronary sinus is better insulated from the ventricular myocardium due 
to a thicker fatty and fibrotic tissue barrier that is more robust than that of 
canines (data not shown). Nevertheless, due to the larger size of human coronary 
sinus anatomy, the migration of such a lead after implantation could cause 
unintended ventricular capture during Stages 2 and 3 of the three-step therapy.  
Such migration may be prevented by cautious implantation to avoid placing the 
CS lead into sub-vessels from which the coil may easily migrate out of, and by 
designing leads that more stably maintain their position after implant.  
 
Further reductions in atrial defibrillation energy may be achieved by thoughtful 
engineering.  Larger impedances require higher voltage shocks to deliver 
adequate defibrillation energy, yet large voltage shocks are more likely to be 
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painful.  Previous studies showed that increasing electrode surface area by using 
multiple cathode or anode electrodes can significantly reduce the overall 
impedance.148  Importantly, such a reduction would also decrease the peak 
voltage necessary for defibrillation, which is directly linked to pain sensation.  
Another strategy is to deliver sequential shocks across multiple vectors using 
several different pairs of electrodes.148-150 This strategy could also be used to 
lower DFTs by eliminating the region of low field gradient created between two 
electrodes that are electrically tied together. In addition to multiple stage therapy, 
the engineering techniques discussed here may be crucial to keeping the atrial 
DFT under the pain threshold and should be explored in future studies.  
 
5.7 Conclusions 
 
In the present study, we found that multiple biphasic shocks were significantly 
more efficacious for cardioversion of AF than monophasic shocks, and that two 
sequential biphasic shocks was optimal in terms of atrial DFT and peak voltage.  
We also showed that a novel three-stage therapy we achieved the lowest atrial 
DFT.  Importantly, the atrial DFT of three-stage therapy is at or below the pain 
threshold (0.19 ± 0.12 J). Finally, our study demonstrated that defibrillation 
vector did not significantly alter atrial DFT.  Based on this study, we conclude 
that three-stage therapy may allow pain-free cardioversion of atrial fibrillation. 
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6 Conclusions and Future Directions 
 
6.1 Concluding Remarks 
 
This dissertation first explored the mechanisms of maintenance and termination 
of ventricular arrhythmias in the ex-vivo whole rabbit heart model of chronic 
myocardial infarction using panoramic optical mapping technique, as presented 
in Chapter 3. It has been shown that the effective size and arrhythmia wave 
propagation patterns of rabbit heart are the most similar to that of the human 
heart. Moreover, the size of the rabbit hearts allows us to use the Langendorff 
perfusion system to perfuse the whole heart and to apply panoramic imaging 
technique to directly visualize the effect of the electric shocks on the whole 
epicardium surface. These techniques facilitate the study of mechanisms of 
arrhythmia in this model as well as accordingly development of more efficient 
defibrillation waveforms with low defibrillation thresholds. 
 
A thin layer of surviving endocardial border zone is typical in this model. We 
showed that the infarct and the border zone played an important role in 
stabilizing and sustaining the reentry VT in the setting of chronic myocardial 
infarction. This finding is consistent with previous theoretical and experimental 
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studies as well as clinical observations that VT is stabilized and sustained by 
functional or anatomical heterogeneity. Sustained monomorphic VT occurs in the 
absence of acute ischemia when the patients have an old myocardial scar. In this 
rabbit model, we found antitachycardia pacing inefficient in termination of VT. 
We also found a phase-dependent mechanism of VT termination by a single 
biphasic shock, which is commonly used by current ICD therapy. This finding is 
consistent with previous finding about the efficacy of a single monophasic shock 
in termination of VT in the same model. The minimum and maximum CVT were 
significantly different in all eight hearts, where the maximum vs. minimum CVT 
of 1BP applied at various phases was 8.6 ± 1.7 vs. 3.7 ± 1.9 V/cm, respectively 
(p=0.0013). Moreover, we found that the minimum and maximum CVT of a 
single monophasic shock were similar to that of a biphasic shock in termination 
of VT. For both shock waveforms, the optimal phase with the minimum CVT 
varied with different hearts, different VT morphology. More extensively, it could 
change with different sizes and locations of the infarction, different sizes and 
locations of defibrillation electrode, etc. Therefore, clinically, this optimal phase 
is impossible for us to measure. 
 
Based on the mechanism of VT termination by a single shock, we generated an 
idea of using sequential multiple shocks that cover all the phases in one VT cycle 
length so that we can achieve the minimum defibrillation energy without the 
need to determine the optimal phase. We tested the multiple shock therapy in the 
same rabbit model with chronic infarction and compared the efficacy of multiple 
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monophasic shocks with multiple biphasic shock. We found that CVT of five 
monophasic shocks is similar to the minimum CVT of a single biphasic shock at 
4.3 ± 1.9 vs. 4.9 ± 2.7 V/cm, respectively (p=0.37). This suggests that we achieved 
the minimum CVT of a single shock successfully using the multiple pulse therapy 
without determining the optimal phase.  
 
We studied the mechanism of termination of VT by multiple shock therapy and 
found that the multiple shocks applied within one VT cycle length terminated VT 
by maintaining virtual cathodes at certain areas of the reentrant circuit. The 
refractory period was prolonged at those areas and the reentrant wave front was 
haunted and vanished when propagated to the refractory areas. Then the reentry 
was unpinned from the anchoring site. To our surprise, in contrast to the 
conventional single shock defibrillation where the biphasic waveform is superior 
than monophasic waveform, we found that the multiple monophasic shocks had a 
significantly higher efficacy than multiple biphasic shocks in termination of VT. 
Based on the VEP theory of defibrillation, we know that biphasic waveform 
generate no VEP because the VEP pattern created by the first phase of the 
biphasic shock is reversed by the second phase. However, low-voltage multiple 
shock therapy terminates VT by maintaining the virtual cathodes throughout a 
VT cycle length. Therefore, multiple monophasic shocks are more efficacious 
than multiple biphasic shocks for this purpose. We could also conclude that both 
panoramic optical mapping technique and VEP theory of defibrillation are 
incredibly crucial in studying the mechanisms of the defibrillation and in 
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developing new efficacious defibrillation waveforms with low defibrillation 
thresholds. 
 
The size of a rabbit heart makes it an optimal model to study the mechanism of 
low-voltage defibrillation in the Langendorff perfusion system and panoramic 
imaging system. However, it is still an ex-vivo experimental model. The 
defibrillation electrodes that we used are two rectangular mesh electrodes 
parallel to each other in the perfusion chamber. The defibrillation thresholds 
could be only presented using the intensity of the electric field across two 
electrodes instead of the real energy that delivered to the heart.  
 
In order to validate the multiple shock therapy, we used a more clinically relevant 
model, which is canine hearts with healing myocardial infarction in vivo, as 
described in Chapter 4. In this model, the myocardial infarction was created by 2 
hours’ LAD ligation. Four days later, the defibrillation study was performed. This 
model has been shown to have an epicardial infarction border zone, which is 
similar to that in human heart. The sized of a dog heart is more close to that of 
the human heart. We adopted multi-electrode mapping technique to study the 
mechanism of arrhythmia. We found that the mechanism of sustained VT in this 
model is mainly monomorphic Figure-of-eight reentry with a common pathway 
or isthmus located at the infarction border zone. We used a 8F RV coil and a 
posterior LV patch as the reference electrode. We tested multiple shock therapy 
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with different number of shocks and found that ten monophasic shocks applied 
within two VT cycle length has the lowest CVT  (0.04 ± 0.02 J), compared to 
three, five, and seven shocks that applied within one VT cycle length. This might 
be due to the reinforcement of VEP effect of multiple monophasic shocks in two 
VT cycles. This study optimized the multiple shock therapy for termination of VT 
and confirmed it as a low-voltage, low-energy defibrillation therapy in an in vivo 
large animal model. 
 
Other than low-voltage defibrillation therapy for ventricular arrhythmias was 
studied and developed in this dissertation, we also aimed to develop a low-
voltage defibrillation therapy for atrial fibrillation to make the pain-free atrial 
ICD therapy possible. The study was presented in Chapter 5, on an in vivo canine 
model of vagally-mediated AF. We took advantage of AF being nonlethal and 
developed a multi-stage therapy. We compared it to multiple shock therapy, and 
tested monophasic and biphasic waveforms for the first-stage therapy. Different 
than the multiple shock therapy for VT, multiple biphasic shocks had 
significantly lower atrial DFT than multiple monophasic shock, which is 
consistent with the finding for traditional a single shock defibrillation. This is 
mainly due to different mechanisms of the arrhythmias. Reentry VT in the last 
two animal models were sustained by a single mother rotor or a common 
pathway. In contrast, AF in this model is sustained by multiple rotors with 
different frequencies, phases, and anatomical locations. Therefore, extinguishing 
all existing rotors is fundamental to the defibrillation of AF. This is better 
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achieved by biphasic shocks, which create a more homogenous VEP pattern than 
monophasic shocks, and provides a mechanistic explanation of our findings in 
the present study.   
 
Another important difference between the defibrillation of VT versus AF is the 
optimal number of shocks.  In a canine infarct model of VT, we found that less 
(three) monophasic shocks had the highest DFT, while more (ten) monophasic 
shocks applied within two VT cycles had the lowest DFT compared to one, three, 
five, and seven monophasic shocks applied within one VT cycle. In the present 
study, we demonstrated that applying more than two biphasic shocks in the first-
stage did not lower the DFT. This difference suggests fundamental differences in 
the mechanisms of defibrillation of a relatively slow and more organized VT wave 
front versus a faster and more disorganized collection of wave fronts seen in AF; 
a longer train of shocks in a short interval could lead to defibrillation failure not 
by failing to terminate the existing disorganized wave fronts per se, but rather, by 
inducing new wave fronts. Moreover, from a neurological point of view, a smaller 
number of shocks is advantageous in developing a painless AF cardioversion 
strategy, as perceived pain increases with increasing number of shocks.  
 
We validated that multi-stage therapy had a significantly lower atrial DFT (0.19 ± 
0.12 J), compared to one-stage and two-stage therapy in all three defibrillation 
vectors that we tested. We didn’t find any significant difference of multi-stage 
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therapy in the three vectors. With this energy level required for atrial 
defibrillation by the multi-stage therapy, we suggest that the pain-free atrial 
defibrillation device is possible. 
 
 
6.2  Future Directions 
  
6.2.1 Mechanisms of Defibrillation using Multi-stage Therapy 
for AF   
The multi-stage therapy developed in this dissertation had achieved significantly 
low-energy for atrial defibrillation, which might be below patient’s pain 
threshold. However, the mechanism of atrial defibrillation using multi-stage 
therapy remains unclear. In order to study the mechanism, we need to take a step 
back from the in vivo animal model to the ex vivo animal model, such as 
Langendorff-perfused whole rabbit heart or isolated canine atria. These two 
animal models would allow us to apply optical mapping technique to visualize the 
effect of every stage during the electrotherapy. It will give us a better 
understanding about how the multi-stage therapy works based on the VEP 
hypothesis of defibrillation. With this knowledge, we can optimize the multi-stage 
therapy, for example, the intervals between each shocks in the first and the 
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second stages, and delays between each stage, the number and duration of 
stimuli for each stage, etc. All these parameter could be explored and optimized 
in the Langendorff-perfused hearts.  
 
At the same time as studying the mechanism of termination of AF by the multi-
stage therapy, we could also work on the automation of the therapy delivery 
algorithm. For example, we need to be able to perform real-time FFT analysis to 
determine the dominant frequency of AF before each stage of the electrotherapy 
in order to determine whether the conversion succeeds or to determine the 
parameters for the next multi-stage therapy when the conversion fails.  
 
Although we found that there are no significant difference in the atrial DFT of 
three different defibrillation vectors in the open chest canine model of vagally-
mediated AF, it would be interesting to test the atrial DFT of rotating-field for the 
first-stage in the multi-stage therapy. Rotating-field was designed and is ready to 
be used for that purpose. We can deliver the multiple (two to three) shocks in the 
first-stage using different defibrillation vectors for each shock to create a electric 
field that is rotating around the atria to create more homogeneous VEP on atria 
tissue that might enhance the efficacy to eliminate mother rotors that sustain AF. 
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6.2.2 Low-voltage Defibrillation therapy for VT in canine 
model of healing infarct  
In this model, we found that the anti-tachycardia pacing is ineffective. However, 
we did not combine the multiple shock therapy with the anti-tachycardia therapy 
together. It would be interesting to test the multi-stage or two-stage therapy (first 
stage and third stage of the multi-stage therapy) in the in vivo canine model of 
healing infarct and ex vivo Langendorff-perfused canine hearts with healing 
infarct to use optical mapping to study the mechanism of termination of VT using 
multi-stage therapy. Especially, it would be interesting to see whether there is any 
difference in the efficacy of multi-stage therapy with respect to the two different 
types of arrhythmia: AF and VT.  
 
Moreover, we used an implanted RV coil to epicardial LV patch as the 
defibrillation vector to test the multiple shock therapy in the canine healing 
infarction model. However, this is not a clinically possible electrode configuration 
for implantation. We should test the multiple shock or multi-stage therapy using 
a transvenously implantable vector system, for example, implanted RV coil to 
implanted cononary sinus coil. We could also use the same real-time FFT 
technique to the VT study for automatic measurement of the VT cycle length for 
setting the parameters of the therapy. 
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6.2.3 Implantable Low-voltage Atrial Defibrillation Therapy 
in canine hearts   
For the multi-stage we developed and validated in the open chest canine hearts, 
we used a vagally-mediated model of acute AF, which doesn’t involve atrial 
remodeling. However, atrial remodeling occurs most of the patients that have 
persistent or permanent AF. In order to reproduce the same substrates setting 
that sustained AF clinically, we could test the multi-stage therapy in a more 
clinically relevant model, chronic rapid atrial pacing canine model of AF. This 
model develops atrial electrical and mechanical remodeling over time. The 
mechanisms of AF might be different in the acute and the chronic model. Thus, it 
will be interest to test and optimize our multi-stage therapy in the chronic model. 
 
In our acute AF model presented in this dissertation, we still used disc electrode 
that sutured to the epicardium for RAA, LAA, and SVC. In the chronic rapid atrial 
pacing model, we could transvenously implant all the defibrillation leads during 
the pacemaker implant and test our multi-stage therapy in the close-chest 
animal. By doing that, we could perform several defibrillation studies to the same 
animal at different time points. The chronic rapid atrial pacing induced atrial 
remodeling and the transnenous lead system is more clinically relevant. We could 
also try to decrease the impedance for each defibrillation vector to lower the 
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energy required for defibrillation. We could use a joint vector, which is 
combining two coils as one electrode to increase the surface area of the electrode. 
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Appendix A 
 
A.1 Multi-Stage Defibrillation Therapy 
 
A.1.1 Hardware 
 
A customized defibrillator was designed to allow us to deliver arbitrary 
defibrillation waveforms. It is comprised of functional blocks of sensing, 
amplification, recording, therapy generation, and therapy delivery. EKG, Atrial 
electrogram (AEG) and ventricular electrogram (VEG) will be continuously 
recorded during each defibrillation study. The cycle length or dominant 
frequency of the arrhythmia will be determined, according to which, the 
parameters of the three-stage defibrillation therapy will be adjusted. Customized 
LabVIEW program and a data acquisition system (PCI-6221, National 
Instruments Corp.) are used to generate shock waveform and pacing waveform 
for the therapy. The delivery of the therapy is triggered by R wave or VEG. The 
electric shocks are delivered through two kepcos power supplies (BOP 100- 4M, 
Kepco Inc.) connected in series or in parallel to generate an maximum output of 
(4 Amp, 200 V) or (8 Amp, 100V), respectively. The pacing stimuli are delivered 
through a stimulus isolator (A385, World Precision Instruments, Inc.) with 
adjustable current output.  
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Figure  A1.  An  illustrating  diagram  of  the  custom  defibrillator  using  for  AF defibrillation. Two analog waveforms and several digital signals were generated for shock, pace, and vector control.   
 
Figure A2. Photograph of defibrillation system. 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A.1.2 Three-stage therapy LabVIEW  
A  LabVIEW  program  was  written  for  one‐stage,  two‐stage,  or  three‐stage defibrillation therapy. All the inter‐stage intervals and the intra‐stage intervals can be  set  according  to  the  cycle  length  of  the  arrhythmia.  Monophasic  or  biphasic waveform with different pulse width and tilt can be selected for shock waveforms. Number of shocks or pacing stimuli can be varied by the user too. 
 
Figure A3. LabVIEW program for three‐stage defibrillation therapy. 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A.1.3 Data analysis software LabVIEW  
A LabVIEW program is written  for display of EKG, atrial, ventricular electrograms, shock  and  pacing  stimuli  applied  that  were  recorded  continuously  during  the experiment.  All the electrograms are synchronized and any arbitrary interval could be measured directly using two cursors.   
There  are  two  major  functions  of  this  program.  First,  it  could  determine  the dominant frequency of the tachyarrhythmia using Fast Fourier Transfrom (FFT) and peak  detection  algorithm  of  the  electrogram  for  a  certain  period  time  confined within two cursors. Second, it could detect the beginning and the end of the multi‐stage  therapy  even  with  multiple  shocks  and  determine  the  dominant  frequency before and after  the  therapy  for each delivered  therapy  in  the whole data  file and output the results into an excel file. 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Figure  A4.  LabVIEW  program  for  electrogram  visualization  and  electrogram analysis.   
A.2  Rotating-field Defibrillation Therapy 
 
A.2.1 Hardware 
 
This defibrillator can rotate the electric shocks among different defibrillation 
vectors within milliseconds. Each vector is controlled by a pair of relay which is 
timed using a digital output from the computer. 
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Figure A5. Sratch of the design of relay box for the rotating‐field defibrillator. It has three  pairs  of  relay  now.  It  can  be  as  many  as  wanted  for  the  number  of defibrillation  vectors.  Usually  three  defibrillation  vectors  can  cover  the  three‐dimensions of the electric field.    
A.2.2 Rotating-field Therapy LabVIEW 
 
This program is meant to be used altogether with NI Multifunction DAQ board, 
switches box, and Kepco machines for generation of several pulses of which each 
pulse can be passed through different electrodes available. The program is 
essentially can be divided into two parts, one part to generate the pulses and the 
other to generate the signals to control the switches. The pulses will be sent 
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through the analog outputs of the NI Multifunction DAQ board after a trigger is 
passed through the digital input of the Multifunction DAQ board. Subsequently, 
the pulses are passed to the Kepco machines for amplifying purpose. The output 
from the Kepco will then be sent to the switches box where the relays are 
controlled by the digital output signals of the Multifunction DAQ board. The final 
output can then be retrieved from the electrodes connected to the relay box. 
 
 
Figure A6. LabVIEW program for rotating‐field defibrillation therapy. 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